<SEC-DOCUMENT>0001193125-24-217444.txt : 20240912
<SEC-HEADER>0001193125-24-217444.hdr.sgml : 20240912
<ACCEPTANCE-DATETIME>20240912060154
ACCESSION NUMBER:		0001193125-24-217444
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20240910
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240912
DATE AS OF CHANGE:		20240912

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Terns Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001831363
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39926
		FILM NUMBER:		241293806

	BUSINESS ADDRESS:	
		STREET 1:		1065 EAST HILLSDALE BLVD., SUITE 100
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		650-525-5535 EXT.101

	MAIL ADDRESS:	
		STREET 1:		1065 EAST HILLSDALE BLVD., SUITE 100
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d878008d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:tern="http://www.ternspharma.com/20240910" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-368">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-09-10_to_2024-09-10">0001831363</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="tern-20240910.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-09-10_to_2024-09-10"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001831363</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-09-10</xbrli:startDate> <xbrli:endDate>2024-09-10</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-379">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-09-10_to_2024-09-10" format="ixt:datemonthdayyearen" id="ixv-380">September&#160;10, 2024</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-381">Terns Pharmaceuticals, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-09-10_to_2024-09-10" format="ixt-sec:stateprovnameen" id="ixv-382">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-383">001-39926</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-384">98-1448275</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:33%"/>
<td style="vertical-align:bottom"/>
<td style="width:31%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-385">1065 East Hillsdale Blvd.</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-386">Suite 100</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-387">Foster City</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-09-10_to_2024-09-10" format="ixt-sec:stateprovnameen" id="ixv-388">California</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-389">94404</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-390">(650)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-391">525-5535</ix:nonNumeric></span></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-09-10_to_2024-09-10" format="ixt-sec:boolballotbox" id="ixv-392">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-09-10_to_2024-09-10" format="ixt-sec:boolballotbox" id="ixv-393">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-09-10_to_2024-09-10" format="ixt-sec:boolballotbox" id="ixv-394">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-09-10_to_2024-09-10" format="ixt-sec:boolballotbox" id="ixv-395">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-396">Common Stock, $0.0001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-397">TERN</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-09-10_to_2024-09-10" format="ixt-sec:exchnameen" id="ixv-398">Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#160;240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-09-10_to_2024-09-10" format="ixt-sec:boolballotbox" id="ixv-399">&#9746;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2024-09-10_to_2024-09-10" format="ixt-sec:boolballotbox" id="ixv-400">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Underwritten Public Offering </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;10, 2024, Terns Pharmaceuticals, Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters named in Schedule 1 thereto (collectively, the &#8220;Underwriters&#8221;), relating to the underwritten public offering (the &#8220;Offering&#8221;) of 11,919,048 shares (the &#8220;Underwritten Shares&#8221;) of the Company&#8217;s common stock, $0.0001 par value per share (the &#8220;Common Stock&#8221;), and, in lieu of Common Stock to certain investors, <span style="white-space:nowrap">pre-funded</span> warrants (the <span style="white-space:nowrap">&#8220;Pre-Funded</span> Warrants&#8221;) to purchase 2,380,952 shares of Common Stock (the &#8220;Warrant Shares&#8221;). Under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable within 30 days from the date of the Underwriting Agreement, to purchase up to 2,145,000 additional shares of Common Stock (the &#8220;Option Shares&#8221; and together with the Underwritten Shares, the &#8220;Shares&#8221;), which the Underwriters exercised in full on September&#160;11, 2024. The closing of the Offering is expected to take place on September&#160;12, 2024. All of the Shares and <span style="white-space:nowrap">Pre-Funded</span> Warrants are being sold by the Company. The offering price of the Shares to the public is $10.50 per share, and the offering price of the <span style="white-space:nowrap">Pre-Funded</span> Warrants to the public is $10.4999 per share underlying each <span style="white-space:nowrap">Pre-Funded</span> Warrant. The Underwriters have agreed to purchase the Shares from the Company pursuant to the Underwriting Agreement at a price of $9.87 per share and the <span style="white-space:nowrap">Pre-Funded</span> Warrants from the Company pursuant to the Underwriting Agreement at a price of $9.869906 per share underlying each <span style="white-space:nowrap">Pre-Funded</span> Warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each <span style="white-space:nowrap">Pre-Funded</span> Warrant has an exercise price per share of Common Stock equal to $0.0001 per share. The exercise price and the number of shares of Common Stock issuable upon exercise of each <span style="white-space:nowrap">Pre-Funded</span> Warrant is subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock. Each <span style="white-space:nowrap">Pre-Funded</span> Warrant is exercisable from the date of issuance by means of a cashless exercise. Under the <span style="white-space:nowrap">Pre-Funded</span> Warrants, the Company may not effect the exercise of any <span style="white-space:nowrap">Pre-Funded</span> Warrant, and a holder will not be entitled to exercise any portion of any <span style="white-space:nowrap">Pre-Funded</span> Warrant that, upon giving effect to such exercise, would cause: (i)&#160;the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) to exceed 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the exercise; or (ii)&#160;the combined voting power of the Company&#8217;s securities beneficially owned by such holder (together with its affiliates) to exceed 4.99% of the combined voting power of all of the Company&#8217;s securities outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the <span style="white-space:nowrap">Pre-Funded</span> Warrant, which percentage may be changed at the holder&#8217;s election to a higher or lower percentage not in excess of 19.99% upon 61 days&#8217; notice to the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in certain circumstances, upon a fundamental transaction, a holder of <span style="white-space:nowrap">Pre-Funded</span> Warrants will be entitled to receive, upon exercise of the <span style="white-space:nowrap">Pre-Funded</span> Warrants, the kind and amount of securities, cash or other property that such holder would have received had they exercised the <span style="white-space:nowrap">Pre-Funded</span> Warrants immediately prior to the fundamental transaction; provided, however, that in the event of a fundamental transaction where the consideration consists solely of cash, solely of marketable securities or a combination thereof, each <span style="white-space:nowrap">Pre-Funded</span> Warrant will be deemed to be exercised in full in a cashless exercise effective immediately prior to and contingent upon the consummation of such fundamental transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing is only a brief description of the terms of the form of <span style="white-space:nowrap">Pre-Funded</span> Warrant, does not purport to be a complete statement of the rights and obligations of the parties thereto and the transactions contemplated thereby, and is qualified in its entirety by reference to the form of <span style="white-space:nowrap">Pre-Funded</span> Warrant, which is filed as Exhibit 4.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company estimates that the net proceeds from the Offering will be approximately $161.9&#160;million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, and including the full exercise of the Underwriters&#8217; option to purchase the Option Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offering was made pursuant to a shelf registration statement on Form <span style="white-space:nowrap">S-3</span> (File <span style="white-space:nowrap">No.&#160;333-269508)</span> that was filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February&#160;1, 2023 and declared effective by the SEC on February&#160;10, 2023. A prospectus supplement relating to the offering has been filed with the SEC. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations, warranties, covenants, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act, and other obligations of the parties. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. The foregoing is only a brief description of the terms of the Underwriting Agreement, does not purport to be a complete statement of the rights and obligations of the parties under the Underwriting Agreement and the transactions contemplated thereby, and is qualified in its entirety by reference to the Underwriting Agreement, which is filed as Exhibit 1.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the legal opinion of Wilmer Cutler Pickering Hale and Dorr LLP relating to the Shares and the <span style="white-space:nowrap">Pre-Funded</span> Warrants is filed as Exhibit 5.1 hereto. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Pricing of Public Offering </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The full text of the press release announcing the pricing of the Offering on September&#160;10, 2024 is attached as Exhibit 99.1 hereto and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Runway </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on current plans, the Company estimates that its existing cash, cash equivalents and marketable securities, together with the estimated net proceeds from the Offering, will be sufficient to enable the Company to fund its operating expenses and capital expenditure requirements into 2028. The Company has based this estimate on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently expects. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"><span style="font-weight:bold">Exhibit<br/>No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d878008dex11.htm">Underwriting Agreement, dated September&#160;10, 2024, between Terns Pharmaceuticals, Inc. and Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d878008dex41.htm">Form of <span style="white-space:nowrap">Pre-Funded</span> Warrant. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d878008dex51.htm">Opinion of Wilmer Cutler Pickering Hale and Dorr LLP. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d878008dex51.htm">Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit&#160;5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d878008dex991.htm">Press Release dated September&#160;10, 2024. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the inline XBRL document).</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cautionary Note Regarding Forward-Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K</span> contains forward-looking statements about the Company within the meaning of the federal securities laws, including the anticipated net proceeds from the Offering, the anticipated closing of the Offering and the sufficiency of the Company&#8217;s cash resources, constitute forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;positioned,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company&#8217;s plans to vary materially, including the risks associated with the satisfaction of customary closing conditions related to the Offering and the initiation, cost, timing, progress, results and utility of the Company&#8217;s current and future research and development activities and preclinical studies and clinical trials. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Company and the offering, please refer to the risk factors identified in the Company&#8217;s SEC reports, including but not limited to its Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2023, and its preliminary prospectus supplement. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">TERNS PHARMACEUTICALS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: September&#160;12, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elona Kogan</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Elona Kogan</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Legal Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d878008dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>Execution Version</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Terns Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11,919,048 Shares of Common Stock, Par Value $0.0001 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to Purchase 2,380,952 Shares of Common Stock </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Underwriting Agreement </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">September&nbsp;10, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TD Securities (USA) LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">several Underwriters listed </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in Schedule 1 hereto </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o TD Securities (USA) LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 Vanderbilt Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10017 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Terns Pharmaceuticals,
Inc., a Delaware corporation (the &#147;Company&#148;), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the &#147;Underwriters&#148;), for whom you are acting as representatives (the &#147;Representatives&#148;),
(i) an aggregate of 11,919,048 shares of common stock, par value $0.0001 per share, of the Company (the &#147;Underwritten Shares&#148;) and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase an aggregate of 2,380,952 shares of
common stock of the Company, at an exercise price equal to $0.0001 per share, in the form attached hereto as Exhibit B (the &#147;Warrants&#148;) and (ii)&nbsp;at the option of the Underwriters, up to an additional 2,145,000 shares of common stock
of the Company (the &#147;Option Shares&#148;). The Underwritten Shares, Warrants and the Option Shares are herein referred to as the &#147;Securities&#148;. The shares of common stock of the Company issuable upon exercise of the Warrants are herein
referred to as the &#147;Warrant Shares&#148;. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Underwritten Shares, the Option Shares and the exercise of the Warrants are referred to herein as the
&#147;Stock&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that there are no additional Underwriters listed on Schedule 1 hereto, all references to the
Representatives and the Underwriters shall refer just to you, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. To the extent only one Representative is listed above, all references to
the term Representatives shall mean Representative in the singular form. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreement with the several Underwriters concerning the
purchase and sale of the Securities, as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Registration Statement</U>. The Company has prepared and filed with the Securities
and Exchange Commission (the &#147;Commission&#148;) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Securities Act&#148;), a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-269508),</FONT> including a prospectus, relating to the Securities and the Warrant Shares. Such registration statement, as amended at the time it became
effective, including the information, if any, deemed pursuant to Rule 430A, 430B or 430C under the Securities Act to be part of the registration statement at the time of its effectiveness (&#147;Rule 430 Information&#148;), is referred to herein as
the &#147;Registration Statement&#148;; and as used herein, the term &#147;Preliminary Prospectus&#148; means each prospectus included in such registration statement (and any amendments thereto) before effectiveness, any prospectus filed with the
Commission pursuant to Rule 424(a) under the Securities Act and the prospectus included in the Registration Statement at the time of its effectiveness that omits Rule 430 Information, and the term &#147;Prospectus&#148; means the prospectus in the
form first used (or made available upon request of purchasers pursuant to Rule 173 under the Securities Act) in connection with confirmation of sales of the Securities. If the Company has filed an abbreviated registration statement pursuant to Rule
462(b) under the Securities Act (the &#147;Rule 462 Registration Statement&#148;), then any reference herein to the term &#147;Registration Statement&#148; shall be deemed to include such Rule 462 Registration Statement. Any reference in this
underwriting agreement (this &#147;Agreement&#148;) to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form <FONT
STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, as of the effective date of the Registration Statement or the date of such Preliminary Prospectus or the Prospectus, as the case may be, and any reference to &#147;amend&#148;,
&#147;amendment&#148; or &#147;supplement&#148; with respect to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any documents filed after such date under the Securities Exchange Act of
1934, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Exchange Act&#148;) that are deemed to be incorporated by reference therein. Capitalized terms used but not defined herein shall have the meanings
given to such terms in the Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the Applicable Time (as defined below), the Company
had prepared the following information (collectively with the pricing information set forth on Annex A, the &#147;Pricing Disclosure Package&#148;): a Preliminary Prospectus dated September&nbsp;9, 2024 and each &#147;free-writing prospectus&#148;
(as defined pursuant to Rule 405 under the Securities Act) listed on Annex A hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Applicable Time&#148; means 7:15 P.M., New
York City time, on September&nbsp;10, 2024. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Purchase of the Securities</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees to issue and sell the Securities to the several Underwriters as provided in this Agreement, and each Underwriter, on
the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase at a price per share of $9.87 (the &#147;Share Purchase Price&#148;) from the
Company the respective number of Underwritten Shares set forth opposite such Underwriter&#146;s name in Schedule 1 hereto, and to purchase at a price of $9.8699 per Warrant (the &#147;Warrant Purchase Price&#148;) from the Company the respective
number of Warrants set forth opposite such Underwriter&#146;s name in Schedule 1 hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company agrees to issue and
sell the Option Shares to the several Underwriters as provided in this Agreement, and the Underwriters, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, shall have the
option to purchase, severally and not jointly, from the Company the Option Shares at the Share Purchase Price less an amount per share equal to any dividends or distributions declared by the Company and payable on the Underwritten Shares but not
payable on the Option Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any Option Shares are to be purchased, the number of Option Shares to be purchased by each Underwriter
shall be the number of Option Shares which bears the same ratio to the aggregate number of Option Shares being purchased as the number of Securities set forth opposite the name of such Underwriter in Schedule 1 hereto (or such number increased as
set forth in Section&nbsp;10 hereof) bears to the aggregate number of Securities being purchased from the Company by the several Underwriters, subject, however, to such adjustments to eliminate any fractional Option Shares as the Representatives in
their sole discretion shall make. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Underwriters may exercise the option to purchase Option Shares at any time in whole, or from time
to time in part, on or before the thirtieth day following the date of the Prospectus, by written notice from the Representatives to the Company. Such notice shall set forth the aggregate number of Option Shares as to which the option is being
exercised and the date and time when the Option Shares are to be delivered and paid for, which may be the same date and time as the Closing Date (as hereinafter defined) but shall not be earlier than the Closing Date nor later than the tenth full
business day (as hereinafter defined) after the date of such notice (unless such time and date are postponed in accordance with the provisions of Section&nbsp;10 hereof). Any such notice shall be given at least two business days prior to the date
and time of delivery specified therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company understands that the Underwriters intend to make a public offering of the
Securities, and initially to offer the Securities on the terms set forth in the Pricing Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and sell Securities to or through any affiliate of an Underwriter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Payment for the Securities shall be made by wire transfer in immediately available funds
to the account specified by the Company to the Representatives in the case of the Underwritten Shares at the offices of Davis Polk&nbsp;&amp; Wardwell LLP, 450 Lexington Avenue, New York, New York 10017 at 10:00 A.M., New York City time on
September&nbsp;12, 2024, or at such other time or place on the same or such other date, not later than the fifth business day thereafter, as the Representatives and the Company may agree upon in writing or, in the case of the Option Shares, on the
date and at the time and place specified by the Representatives in the written notice of the Underwriters&#146; election to purchase such Option Shares. The time and date of such payment for the Underwritten Shares and Warrants is referred to herein
as the &#147;Closing Date,&#148; and the time and date for such payment for the Option Shares, if other than the Closing Date, is herein referred to as the &#147;Additional Closing Date.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment for the Securities to be purchased on the Closing Date or the Additional Closing Date, as the case may be, shall be made against
delivery to the Representatives for the respective accounts of the several Underwriters of the Securities to be purchased on such date or the Additional Closing Date, as the case may be, with any transfer taxes payable in connection with the sale of
such Securities duly paid by the Company. Delivery of the Underwritten Shares and Option Shares shall be made through the facilities of The Depository Trust Company (&#147;DTC&#148;) unless the Representatives shall otherwise instruct. The Warrants
shall be delivered to the purchasers of the Warrants (or to the Representatives as directed by the Representatives), in definitive form, registered in such names and in such denominations as the Representatives shall request in writing no later than
one business day prior to the Closing Date. The Warrants will be made available for inspection by the Representatives on the business day prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the Company and the Representatives shall instruct the purchasers of the Warrants in the public offering to
make payment for the Warrants on the Closing Date to the Company by wire transfer in immediately available funds to the account specified by the Company at a purchase price of $10.4999 per Warrant, in lieu of payment by the Underwriters for such
Warrants, and the Company shall deliver such Warrants to such purchasers on the Closing Date in definitive form against such payment, in lieu of the Company&#146;s obligation to deliver such Warrants to the Underwriters. The Company shall promptly
(but in no event later than the Closing Date) pay $0.629994 per warrant (the &#147;Warrant Underwriting Discount&#148;) to the Representatives by wire transfer in immediately available funds to the account specified by the Representatives, provided
however, that the Company agrees that the Representatives will be entitled at their discretion to set off the payment for the Underwritten Shares against the aggregate Warrant Underwriting Discount payable to the Representatives, and any excess
amount will remain due and payable to the Company on the Closing Date. In the event the purchasers of the Warrants in the offering fail to make payment to the Company for all or part of the Warrants on the Closing Date, the Underwriters agree to
make payment to the Company for such Warrants at a price per Warrant equal to the Warrant Purchase Price; provided, however, that the Representatives may elect, by written notice to the Company, to receive shares of common stock of the Company in
lieu of all or a portion of such Warrants to be delivered to the Underwriters under this Agreement at a price per share equal to the Share Purchase Price (the &#147;Substitute Shares&#148;). The aggregate amount of Substitute Shares and Warrants to
be delivered to the Representatives hereunder may be reallocated at the discretion of the Representatives no later than the business day prior to the Closing Date, to increase or decrease the number of Substitute Shares or Warrants, provided that
the aggregate number of Substitute Shares and Warrants issued does not exceed 14,300,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company acknowledges and agrees that the Representatives and the other Underwriters
are acting solely in the capacity of an arm&#146;s length contractual counterparty to the Company with respect to the offering of Securities contemplated hereby (including in connection with determining the terms of the offering) and not as a
financial advisor or a fiduciary to, or an agent of, the Company or any other person. Additionally, neither the Representatives nor any other Underwriter is advising the Company or any other person as to any legal, tax, investment, accounting or
regulatory matters in any jurisdiction. The Company shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and neither
the Representatives nor the other Underwriters shall have any responsibility or liability to the Company with respect thereto. Any review by the Representatives and the other Underwriters of the Company, the transactions contemplated hereby or other
matters relating to such transactions will be performed solely for the benefit of the Underwriters and shall not be on behalf of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Representations and Warranties of the Company</U>. The Company represents and warrants to each Underwriter that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Preliminary Prospectus.</I> No order preventing or suspending the use of any Preliminary Prospectus has been issued by
the Commission, and each Preliminary Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, complied in all material respects with the Securities Act, and no Preliminary Prospectus, at the time of filing thereof,
contained any untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company
makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives
expressly for use in any Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Pricing Disclosure Package</I>. The Pricing Disclosure Package as of the Applicable Time did not, and as of the Closing
Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to
the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Company in writing by such Underwriter through the Representatives expressly for use in such Pricing Disclosure Package, it being understood and agreed that the only such information furnished by
any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. No statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure Package and no statement of material fact included in
the Pricing Disclosure Package that is required to be included in the Prospectus has been omitted therefrom. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Issuer
Free Writing Prospectus. </I>Other than the Registration Statement, the Preliminary Prospectus and the Prospectus, the Company (including its agents and representatives, other than the Underwriters in their capacity as such) has not prepared, made,
used, authorized, approved or referred to and will not prepare, make, use, authorize, approve or refer to any &#147;written communication&#148; (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an
offer to buy the Securities (each such communication by the Company or its agents and representatives (other than a communication referred to in clause (i)&nbsp;below) an &#147;Issuer Free Writing Prospectus&#148;) other than (i)&nbsp;any document
not constituting a prospectus pursuant to Section&nbsp;2(a)(10)(a) of the Securities Act or Rule 134 under the Securities Act or (ii)&nbsp;the documents listed on Annex A hereto, each electronic road show, each electronic investor presentation and
any other written communications approved in writing in advance by the Representatives. Each such Issuer Free Writing Prospectus complies in all material respects with the Securities Act, has been or will be (within the time period specified in Rule
433) filed in accordance with the Securities Act (to the extent required thereby) and does not conflict with the information contained in the Registration Statement or the Pricing Disclosure Package, and, when taken together with the Preliminary
Prospectus accompanying, or delivered prior to delivery of, or filed prior to the first use of, such Issuer Free Writing Prospectus, did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any
untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no
representation or warranty with respect to any statements or omissions made in each such Issuer Free Writing Prospectus or Preliminary Prospectus in reliance upon and in conformity with information relating to any Underwriter furnished to the
Company in writing by such Underwriter through the Representatives expressly for use in such Issuer Free Writing Prospectus or Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter
consists of the information described as such in Section&nbsp;7(b) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Emerging Growth Company</I>. As of the
date hereof, the Company is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act (an &#147;Emerging Growth Company&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)
<I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Materials. </I>The Company (i)&nbsp;has not alone engaged in any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications (as defined below) other than <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communications with the consent of the Representatives (x)&nbsp;with entities that are qualified institutional buyers (&#147;QIBs&#148;) within the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within
the meaning of Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act (&#147;IAIs&#148;) and otherwise in compliance with the requirements of Section&nbsp;5(d) of the Securities Act or (y)&nbsp;with entities that the Company
reasonably believed to be QIBs or IAIs and otherwise in compliance with the requirements of Rule 163B under the Securities Act and (ii)&nbsp;has not authorized anyone other than the Representatives to engage in <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;Testing-the-Waters</FONT></FONT> Communication&#148; means any oral or written communication with
potential investors undertaken in reliance on either Section&nbsp;5(d) of, or Rule 163B under, the Securities Act. The Company has not distributed or approved for distribution any Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications (as defined below) other than those listed on Annex B hereto. &#147;Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication&#148; means any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405 under the Securities Act. Any individual
Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication does not conflict with the information contained in the Registration Statement or the Pricing Disclosure Package, complied in
all material respects with the Securities Act, and when taken together with the Pricing Disclosure Package as of the Applicable Time, did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain
any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Registration Statement and Prospectus.</I> The Registration Statement has been declared effective by the Commission. No
order suspending the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act against the Company or related to the offering of the
Securities has been initiated, or to the knowledge of the Company, threatened by the Commission; as of the applicable effective date of the Registration Statement and any post-effective amendment thereto, the Registration Statement and any such
post-effective amendment complied and will comply in all material respects with the applicable requirements of the Securities Act, and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to
be stated therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing Date and as of the Additional Closing Date, as the case may be,
the Prospectus will comply in all material respects with the Securities Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the
Representatives expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto, it being understood and agreed that the only such information furnished by any Underwriter consists of the information
described as such in Section&nbsp;7(b) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Incorporated Documents.</I> The documents incorporated by reference
in the Registration Statement, the Prospectus and the Pricing Disclosure Package, when they were filed with the Commission conformed in all material respects to the requirements of the Exchange Act, and none of such documents contained any untrue
statement of a material fact or omitted to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and any further documents so filed and incorporated by reference
in the Registration Statement, the Prospectus or the Pricing Disclosure Package, when such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and will not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Financial Statements.</I> The financial statements (including the related notes thereto) of the Company and its
consolidated subsidiaries included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects with the applicable requirements of the Securities Act and the Exchange
Act, as applicable, and present fairly in all material respects, the financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations and the changes in their cash flows for the
periods specified; such financial statements have been prepared in conformity with generally accepted accounting principles (&#147;GAAP&#148;) in the United States applied on a consistent basis throughout the periods covered thereby, except in the
case of unaudited interim financial statements, which are subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and do not contain certain footnotes as permitted by the applicable rules of the Commission, and any supporting
schedules included or incorporated by reference in the Registration Statement present fairly in all material respects, the information required to be stated therein; and the other financial information included or incorporated by reference in the
Registration Statement, the Pricing Disclosure Package and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and presents fairly in all material respects the information shown thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>No Material Adverse Change.</I> Since the date of the most recent
financial statements of the Company included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i)&nbsp;there has not been any change in the capital stock (other than the issuance of
shares of common stock upon exercise of stock options and warrants described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration Statement, the Pricing Disclosure Package and
the Prospectus), short-term debt or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material
adverse change, or any development that would reasonably be expected to result in a material adverse change, in or affecting the business, properties, management, financial position, stockholders&#146; equity, results of operations or prospects of
the Company and its subsidiaries taken as a whole; (ii)&nbsp;neither the Company nor any of its subsidiaries has entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its
subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii)&nbsp;neither the Company nor any of its subsidiaries has sustained any loss
or interference with its business that is material to the Company and its subsidiaries taken as a whole and that is either from fire, explosion, pandemic, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or
dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Organization and Good Standing.</I> The Company and each of its subsidiaries have been duly organized and are validly
existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their respective ownership or lease of property or the conduct
of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, except where the failure to be so qualified or
in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the business, properties, management, financial position, stockholders&#146; equity, results of operations or prospects
of the Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations under this Agreement (a &#147;Material Adverse Effect&#148;). The subsidiaries listed in Exhibit 21.1 to the Company&#146;s Annual Report on
Form <FONT STYLE="white-space:nowrap">10-K</FONT> are the only significant subsidiaries of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)
<I>Capitalization.</I> All the outstanding shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and are not subject to any <FONT
STYLE="white-space:nowrap">pre-emptive</FONT> or similar rights that have not been duly waived or satisfied; except as described in or expressly contemplated by the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are
no outstanding rights (including, without limitation, <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights, that have not been duly waived or satisfied), warrants or options to acquire, or instruments convertible into or exchangeable for, any
shares of capital </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
stock or other equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any capital
stock of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options; the capital stock of the Company conforms in all material respects to the description thereof contained in the
Registration Statement, the Pricing Disclosure Package and the Prospectus; and all the outstanding shares of capital stock or other equity interests of each subsidiary owned, directly or indirectly, by the Company have been duly and validly
authorized and issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> (except as otherwise described in the Registration Statement, the Pricing Disclosure Package and the Prospectus,) and are owned directly or indirectly
by the Company, free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Stock Options. </I>With respect to the stock options (the &#147;Stock Options&#148;) granted pursuant to the stock-based
compensation plans of the Company and its subsidiaries (the &#147;Company Stock Plans&#148;), (i) each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective (the
&#147;Grant Date&#148;) by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary
number of votes or written consents, and the award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (ii)&nbsp;each such grant was made in accordance with the terms of the applicable Company Stock Plan
and all other applicable laws and regulatory rules or requirements, and (iii)&nbsp;each such grant was properly accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company and disclosed in the
Company&#146;s filings with the Commission in accordance with the Exchange Act and all other applicable laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Due
Authorization.</I> The Company has full right, power and authority to execute and deliver this Agreement and to perform its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it
of this Agreement and the consummation by it of the transactions contemplated hereby has been duly and validly taken. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)
<I>Underwriting Agreement. </I>This Agreement has been duly authorized, executed and delivered by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>The
Securities and the Warrant Shares. </I>(i)&nbsp;The Underwritten Shares and Option Shares to be issued and sold by the Company hereunder have been duly authorized by the Company and, when issued and delivered and paid for as provided herein, will be
duly and validly issued, will be fully paid and nonassessable and will conform to the descriptions thereof in the Registration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Statement, the Pricing Disclosure Package and the Prospectus; (ii)&nbsp;the Warrants have been duly authorized by the Company and, when executed and delivered by the Company in accordance with
this Agreement, will constitute valid and legally binding agreements of the Company, enforceable against the Company in accordance with their terms, except as enforceability may be limited by applicable bankruptcy, insolvency or similar laws
affecting creditors&#146; rights generally or by equitable principles relating to enforceability; (iii)&nbsp;the Warrant Shares to be issued by the Company upon exercise of the Warrants, as provided therein, have been duly and validly authorized
and, when issued and delivered upon exercise as provided under the Warrants, will be duly and validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and will conform in all material respects to the descriptions thereof
in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and (iv)&nbsp;the issuance of the Securities and the Warrant Shares is not subject to any preemptive or similar rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I>Description of the Underwriting Agreement.</I> This Agreement conforms in all material respects to the description
thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <I>No Violation or
Default.</I> Neither the Company nor any of its subsidiaries is (i)&nbsp;in violation of its charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with
notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which
the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any property or asset of the Company or any of its subsidiaries is subject; or (iii)&nbsp;in violation of any law or statute or
any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (ii)&nbsp;and (iii) above, for any such default or violation that would not, individually or in the aggregate,
have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <I>No Conflicts. </I>The execution, delivery and performance by the Company of this
Agreement and the Warrants, the issuance and sale of the Securities and the Warrant Shares and the consummation of the transactions contemplated by this Agreement and the Warrants or the Pricing Disclosure Package and the Prospectus will not
(i)&nbsp;conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or
encumbrance upon any property, right or asset of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party
or by which the Company or any of its subsidiaries is bound or to which any property, right or asset of the Company or any of its subsidiaries is subject, (ii)&nbsp;result in any violation of the provisions of the charter or <FONT
STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents of the Company or any of its subsidiaries or (iii)&nbsp;result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator
or governmental or regulatory authority, except, in the case of clauses (i)&nbsp;and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in the aggregate, have a Material
Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <I>No Consents Required.</I> No consent, approval, authorization, order,
registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Securities and the
consummation of the transactions contemplated by this Agreement, except for the registration of the Securities under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications as may be required under
applicable state securities laws in connection with the purchase and distribution of the Securities by the Underwriters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <I>Legal Proceedings.</I> Except as described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, there are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings (&#147;Actions&#148;) pending to which the Company or any of its subsidiaries is or, may reasonably be
expected to become a party or to which any property of the Company or any of its subsidiaries is or may be the subject that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, would reasonably be
expected to have a Material Adverse Effect; to the knowledge of the Company, no such Actions are threatened or contemplated by any governmental or regulatory authority or threatened by others; and (i)&nbsp;there are no current or pending Actions
that are required under the Securities Act to be described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so described in the Registration Statement, the Pricing Disclosure Package and the Prospectus and
(ii)&nbsp;there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package
or the Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <I>Independent Accountants</I>. Ernst&nbsp;&amp; Young LLP, who have certified certain financial statements of the Company
and its subsidiaries, is an independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board
(United States) and as required by the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Title to Real and Personal Property</I>. The Company and its
subsidiaries have good and marketable title in fee simple (in the case of real property) to, or have valid rights to lease or otherwise use, all items of real and personal property that are material to the respective businesses of the Company and
its subsidiaries, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i)&nbsp;do not materially interfere with the use made and proposed to be made of such property by the Company
and its subsidiaries or (ii)&nbsp;would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <I>Intellectual Property.</I> Except as disclosed in the Pricing Disclosure Package and the final Prospectus, (i)&nbsp;the
Company and its subsidiaries own or have the right to use all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, domain names and other source indicators, copyrights and
copyrightable works, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, systems, procedures, proprietary or confidential information and all other worldwide intellectual property, industrial property and proprietary rights
(collectively, &#147;Intellectual Property&#148;) used, or as contemplated to be used, in the Registration Statement, in the conduct of their respective businesses; (ii)&nbsp;the Intellectual Property owned by the Company and its subsidiaries and,
to the Company&#146;s knowledge, the Intellectual Property licensed to the Company and its subsidiaries, are valid, subsisting and enforceable, and there is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim
by others challenging the validity, scope or enforceability of any such Intellectual Property; (iii)&nbsp;to the knowledge of the Company, Company&#146;s and its subsidiaries&#146; conduct of their respective businesses does not infringe,
misappropriate or otherwise violate, and has not infringed, misappropriated or otherwise violated, any valid Intellectual Property of any person; (iv)&nbsp;the Company and its subsidiaries have not received any notice of any claim challenging the
Company&#146;s rights in or to its Intellectual Property and there are no actual or, to the knowledge of the Company, threatened claims alleging that the Company or any of its subsidiaries infringe, misappropriate or otherwise violate any third
party Intellectual Property; (v)&nbsp;to the knowledge of the Company, the Intellectual Property of the Company and its subsidiaries is not being, and has not been, infringed, misappropriated or otherwise violated by any person; (vi)&nbsp;to the
knowledge of the Company, all employees or contractors engaged in the development of Intellectual Property owned by the Company or its subsidiaries, on behalf of the Company or any subsidiary of the Company have executed an invention assignment
agreement or other agreement whereby such employees or contractors assign all of their right, title and interest in and to such Intellectual Property to the Company or the applicable subsidiary, and to the Company&#146;s knowledge no such agreement
has been breached or violated; and (vii)&nbsp;to the knowledge of the Company, the Company and its subsidiaries use, and have used, commercially reasonable efforts to appropriately maintain all information intended by the Company to be maintained as
a trade secret. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <I>No Undisclosed Relationships</I>. No relationship, direct or indirect, exists between or among the
Company or any of its subsidiaries, on the one hand, and the directors, officers, stockholders, customers, suppliers or other affiliates of the Company or any of its subsidiaries, on the other, that is required by the Securities Act to be described
in each of the Registration Statement and the Prospectus and that is not so described in such documents and in the Pricing Disclosure Package. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <I>Investment Company Act</I>. The Company is not and, after giving
effect to the offering and sale of the Securities and the application of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be required to register as an &#147;investment
company&#148; or an entity &#147;controlled&#148; by an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the
&#147;Investment Company Act&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <I>Taxes.</I> The Company and its subsidiaries have paid all federal, state,
local and foreign taxes and filed all tax returns required to be paid or filed through the date hereof except where the failure to pay such taxes or file such tax returns would not, individually or in the aggregate, have a Material Adverse Effect;
and except as otherwise disclosed in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no material tax deficiency that has been, or could reasonably be expected to be, asserted against the Company or any
of its subsidiaries or any of their respective properties or assets. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <I>Licenses and Permits.</I> The Company and its
subsidiaries possess all licenses, <FONT STYLE="white-space:nowrap">sub-licenses,</FONT> certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign
governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as described in each of the Registration Statement, the Pricing Disclosure Package and
the Prospectus, except where the failure to possess or make the same would not, individually or in the aggregate, have a Material Adverse Effect; and except as described in each of the Registration Statement, the Pricing Disclosure Package and the
Prospectus, neither the Company nor any of its subsidiaries has received notice of any revocation or modification of any such license, <FONT STYLE="white-space:nowrap">sub-license,</FONT> certificate, permit or authorization or has any reason to
believe that any such license, <FONT STYLE="white-space:nowrap">sub-license,</FONT> certificate, permit or authorization will not be renewed in the ordinary course, except for such revocations, modifications, or
<FONT STYLE="white-space:nowrap">non-renewals,</FONT> that would not, whether individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <I>No Labor Disputes.</I> No labor disturbance by or dispute with employees of the Company or any of its subsidiaries
exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its or its subsidiaries&#146; principal suppliers,
contractors or customers, except as would not be reasonably expected to have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received any notice of cancellation or termination with respect to any collective bargaining
agreement to which it is a party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <I>Certain Environmental Matters</I>. (i)&nbsp;The Company and its
subsidiaries (x)&nbsp;are in compliance with all, and have not violated any, applicable federal, state, local and foreign laws (including common law), rules, regulations, requirements, decisions, judgments, decrees, orders and other legally
enforceable requirements relating to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#147;Environmental Laws&#148;); (y)
have received and are in compliance with all, and have not violated any, permits, licenses, certificates or other authorizations or approvals required of them under any Environmental Laws to conduct their respective businesses; and (z)&nbsp;have not
received notice of any actual or potential liability or obligation under or relating to, or any actual or potential violation of, any Environmental Laws, including for the investigation or remediation of any disposal or release of hazardous or toxic
substances or wastes, pollutants or contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;there are no costs or liabilities associated with Environmental Laws of or
relating to the Company or its subsidiaries, except in the case of each of (i)&nbsp;and (ii) above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (iii)&nbsp;except
as described in each of the Pricing Disclosure Package and the Prospectus, (x)&nbsp;there is no proceeding that is pending, or that is known by the Company to be contemplated, against the Company or any of its subsidiaries under any Environmental
Laws in which a governmental entity is also a party, other than such proceeding regarding which the Company reasonably believes no monetary sanctions of $100,000 or more will be imposed, (y)&nbsp;the Company and its subsidiaries are not aware of any
facts or issues regarding compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants, that would reasonably be expected to have a
material effect on the capital expenditures, earnings or competitive position of the Company and its subsidiaries, and (z)&nbsp;none of the Company or its subsidiaries anticipates material capital expenditures relating to any Environmental Laws.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <I>Compliance with ERISA</I>. (i)&nbsp;Each employee benefit plan, within the meaning of Section&nbsp;3(3) of the
Employee Retirement Income Security Act of 1974, as amended (&#147;ERISA&#148;), for which the Company or any member of its &#147;Controlled Group&#148; (defined as any entity, whether or not incorporated, that is under common control with the
Company within the meaning of Section&nbsp;4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section&nbsp;414(b),(c),(m) or (o)&nbsp;of the Internal Revenue Code of 1986, as amended (the
&#147;Code&#148;) would have any liability (each, a &#147;Plan&#148;) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code;
(ii)&nbsp;no prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption;
(iii)&nbsp;for each Plan that is subject to the funding rules of Section&nbsp;412 of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Code or Section&nbsp;302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards (within the meaning of
Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code) applicable to such Plan; (iv)&nbsp;no Plan is, or is reasonably expected to be, in &#147;at risk status&#148; (within the meaning of Section&nbsp;303(i) of ERISA) and no Plan that is a
&#147;multiemployer plan&#148; within the meaning of Section&nbsp;4001(a)(3) of ERISA is in &#147;endangered status&#148; or &#147;critical status&#148; (within the meaning of Sections 304 and 305 of ERISA); (v) the fair market value of the assets
of each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no &#147;reportable event&#148; (within the meaning of Section&nbsp;4043(c) of ERISA and the
regulations promulgated thereunder) has occurred or is reasonably expected to occur; (vii)&nbsp;each Plan that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified, and nothing has occurred, whether by action or by
failure to act, which would cause the loss of such qualification; (viii)&nbsp;neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions
to the Plan or premiums to the Pension Benefit Guaranty Corporation, in the ordinary course and without default) in respect of a Plan (including a &#147;multiemployer plan&#148; within the meaning of Section&nbsp;4001(a)(3) of ERISA); and
(ix)&nbsp;none of the following events has occurred or is reasonably likely to occur: (A)&nbsp;a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the
current fiscal year of the Company and its Controlled Group affiliates compared to the amount of such contributions made in the Company&#146;s and its Controlled Group affiliates&#146; most recently completed fiscal year; or (B)&nbsp;a material
increase in the Company and its subsidiaries&#146; &#147;accumulated post-retirement benefit obligations&#148; (within the meaning of Accounting Standards Codification Topic <FONT STYLE="white-space:nowrap">715-60)</FONT> compared to the amount of
such obligations in the Company and its subsidiaries&#146; most recently completed fiscal year, except in each case with respect to the events or conditions set forth in (i)&nbsp;through (ix) hereof, as would not, individually or in the aggregate,
be reasonably expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <I>Disclosure Controls</I>. The Company and its
subsidiaries, on a consolidated basis, maintain an effective system of &#147;disclosure controls and procedures&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Exchange Act) that complies with the requirements of
the Exchange Act and that has been designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods
specified in the Commission&#146;s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions regarding
required disclosure. The Company and its subsidiaries, on a consolidated basis, have carried out evaluations of the effectiveness of their disclosure controls and procedures as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> of the
Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) <I>Accounting Controls.</I> The Company and its subsidiaries maintain
systems of &#147;internal control over financial reporting&#148; (as defined in Rule 13a-15(f) of the Exchange Act) that comply with the applicable requirements of the Exchange Act and have been designed by, or under the supervision of, their
respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP. The Company and its subsidiaries maintain internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific
authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with
management&#146;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and
(v)&nbsp;interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Prospectus and the Pricing Disclosure Package fairly presents the information called for in all material
respects and is prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no material weaknesses in the
Company&#146;s internal controls. The Company&#146;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i)&nbsp;all significant deficiencies and material weaknesses in the design or operation of internal
controls over financial reporting which have adversely affected or are reasonably likely to adversely affect the Company&#146;s ability to record, process, summarize and report financial information; and (ii)&nbsp;any fraud, whether or not material,
that involves management or other employees who have a significant role in the Company&#146;s internal controls over financial reporting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) <I>eXtensible Business Reporting Language</I>. The interactive data in eXtensible Business Reporting Language included or
incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) <I>Insurance. </I>The Company and its subsidiaries have insurance covering their respective properties, operations,
personnel and businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as the Company reasonably believes are adequate to protect the Company and its subsidiaries and their
respective businesses; and neither the Company nor any of its subsidiaries has (i)&nbsp;received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to
continue such insurance or (ii)&nbsp;any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary
to continue its business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Cybersecurity; Data Protection. </I>Except as would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect,<I> </I>(i)<I></I>&nbsp;the Company and its subsidiaries&#146; information technology assets and equipment, computers, systems, networks, hardware, software,
websites, applications, and databases (collectively, &#147;IT Systems&#148;) are adequate for, and operate and perform as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, free and
clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants; (ii)&nbsp;the Company and its subsidiaries have implemented and maintained commercially reasonable controls, policies, procedures, and safeguards
to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data (including all personal, personally identifiable, sensitive, confidential or regulated data
(&#147;Personal Data&#148;)) used in connection with their businesses, and there have been no breaches, violations, outages or unauthorized uses of or accesses to the same, except for those that have been remedied without material cost or liability
or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same; and (iii)&nbsp;the Company and its subsidiaries are presently in compliance with all applicable laws or statutes and all
judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of
such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification (&#147;Data Security Obligations&#148;). The Company has not received any written notification of or written complaint regarding, and is unaware of any
other facts that, individually or in the aggregate, would reasonably indicate material <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Data Security Obligation, and there is no action, suit or proceeding by or before any court or
governmental agency, authority or body pending or, to the knowledge of the Company, threatened alleging <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Data Security Obligation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) <I>No Unlawful Payments.</I> Neither the Company nor any of its subsidiaries nor any director, officer or employee of the
Company or any of its subsidiaries nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has (i)&nbsp;used any corporate funds for any unlawful
contribution, gift, entertainment or other unlawful expense relating to political activity; (ii)&nbsp;made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or
domestic government official or employee, including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party
or party official or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the
United Kingdom or any other applicable anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate,
payoff, influence payment, kickback or other unlawful or improper payment or benefit. The Company and its subsidiaries have instituted, maintain and enforce, and will continue to maintain and enforce policies and procedures designed to promote and
ensure compliance with all applicable anti-bribery and anti-corruption laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) <I>Compliance with Anti-Money Laundering
Laws</I>. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions
Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar rules, regulations or
guidelines issued, administered or enforced by any governmental agency (collectively, the &#147;Anti-Money Laundering Laws&#148;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator
involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) <I>No Conflicts with Sanctions Laws. </I>Neither the Company nor any of its subsidiaries, directors, officers, or
employees, nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any sanctions administered or enforced by
the U.S. government, (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#147;OFAC&#148;) or the U.S. Department of State and including, without limitation, the designation as a
&#147;specially designated national&#148; or &#147;blocked person&#148;), the United Nations Security Council (&#147;UNSC&#148;), the European Union, His Majesty&#146;s Treasury (&#147;HMT&#148;) or other relevant sanctions authority (collectively,
&#147;Sanctions&#148;), nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or target of Sanctions, including, without limitation, the
<FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic, the Crimea region of Ukraine, Cuba, Iran, North Korea and Syria (each, a
&#147;Sanctioned Country&#148;); and the Company will not directly or indirectly use the proceeds of the offering of the Securities hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or
other person or entity (i)&nbsp;to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii)&nbsp;to fund or facilitate any activities of or
business in any Sanctioned Country or (iii)&nbsp;in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. Since
the Company&#146;s inception, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or
the target of Sanctions or with any Sanctioned Country. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) <I>No Restrictions on Subsidiaries</I>. No subsidiary of the Company is
currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary&#146;s capital stock or
similar ownership interest, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&#146;s properties or assets to the Company or any other subsidiary of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) <I>No Broker&#146;s Fees.</I> Neither the Company nor any of its subsidiaries is a party to any contract, agreement or
understanding with any person (other than this Agreement) that would give rise to a valid claim against any of them or any Underwriter for a brokerage commission, finder&#146;s fee or like payment in connection with the offering and sale of the
Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) <I>No Registration Rights</I>. No person has the right to require the Company or any of its subsidiaries
to register any securities for sale under the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Securities, except for such rights as have been duly waived. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) <I>No Stabilization.</I> Neither the Company nor any of its subsidiaries or, to the Company&#146;s knowledge, other
affiliates has taken, directly or indirectly, without giving effect to activities by the Underwriters, any action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the price of the
Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) <I>Margin Rules</I>. Neither the issuance, sale and delivery of the Securities nor the application of the
proceeds thereof by the Company as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation
of such Board of Governors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) <I>Forward-Looking Statements.</I> No forward-looking statement (within the meaning of
Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act) included or incorporated by reference in any of the Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or reaffirmed without a
reasonable basis or has been disclosed other than in good faith. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) <I>Statistical and Market Data.</I> Nothing has come to the attention
of the Company that has caused the Company to believe that the statistical and market-related data included or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus is not based on or
derived from sources that are reliable and accurate in all material respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) <I>Sarbanes-Oxley Act</I>. There is and
has been no failure on the part of the Company or any of the Company&#146;s directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations
promulgated in connection therewith (the &#147;Sarbanes-Oxley Act&#148;), including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) <I>Status under the Securities Act</I>. At the time of filing the Registration Statement and any post-effective amendment
thereto, at the earliest time thereafter that the Company or any offering participant made a <I>bona fide</I> offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the Securities and at the date hereof, the Company was not and is
not an &#147;ineligible issuer,&#148; as defined in Rule 405 under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) <I>No Ratings</I>. There are
(and prior to the Closing Date, will be) no debt securities, convertible securities or preferred stock issued or guaranteed by the Company or any of its subsidiaries that are rated by a &#147;nationally recognized statistical rating
organization&#148;, as such term is defined in Section&nbsp;3(a)(62) under the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) <I>Regulatory Matters;
Products and Product Candidates</I>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company (collectively with its subsidiaries) and except, in each case, as would not, individually or in
the aggregate, have a Material Adverse Effect: (i)&nbsp;has operated and currently operates its business in compliance with all Health Care Laws (as defined below) applicable to the ownership, testing, development, manufacture, packaging,
processing, use, distribution, storage, import, export or disposal of any of the Company&#146;s or its subsidiaries&#146; product candidates or any product manufactured or distributed by the Company; (ii)&nbsp;has not received any FDA Form 483,
written notice of adverse finding, warning letter, untitled letter or other correspondence or written notice from any court or arbitrator or governmental or regulatory authority alleging or asserting
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with (A)&nbsp;any Health Care Laws or (B)&nbsp;any licenses, certificates, approvals, clearances, exemptions, authorizations, permits and supplements or amendments thereto required by any such
Health Care Laws (&#147;Regulatory Authorizations&#148;); (iii) possesses all Regulatory Authorizations required to conduct its business as currently conducted, and such Regulatory Authorizations are valid and in full force and effect and the
Company is not in violation of any term of any such Regulatory Authorizations; (iv)&nbsp;has not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
action from the Food and Drug Administration (&#147;FDA&#148;), the Department of Health and Human Services or any comparable foreign or other regulatory authority to which they are subject
(collectively, the &#147;Applicable Regulatory Authorities&#148;) alleging that any product of the Company is in violation of any Health Care Laws or Regulatory Authorizations and has no knowledge that the Applicable Regulatory Authorities or any
other third party is threatening any such claim, litigation, arbitration, action, suit, investigation or proceeding; (v)&nbsp;has not received written notice that any of the Applicable Regulatory Authorities has taken, is taking or intends to take
action to limit, suspend, or revoke any Regulatory Authorizations and has no knowledge that any of the Applicable Regulatory Authorities is considering such action; (vi)&nbsp;has filed, obtained, maintained or submitted all material reports,
documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws or Regulatory Authorizations and, to the knowledge of the Company, that all such reports, documents, forms,
notices, applications, records, claims, submissions and supplements or amendments were complete and correct on the date filed (or were materially corrected or supplemented by a subsequent submission); (vii) is not a party to and does not have any
ongoing reporting obligations pursuant to any corporate integrity agreements, deferred or <FONT STYLE="white-space:nowrap">non-prosecution</FONT> agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar
agreements with or imposed by any Applicable Regulatory Authority; and (viii)&nbsp;along with its employees, officers and directors, has not been excluded, suspended or debarred from participation in any government health care program or human
clinical research and, to the knowledge of the Company, is not subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;Health Care Laws&#148; means Title XVIII of the Social Security Act, 42 U.S.C. &#167;&#167; 1395-1395hhh (the
Medicare statute); Title XIX of the Social Security Act, 42 U.S.C. &#167;&#167; 1396-1396v (the Medicaid statute); the Federal Anti-Kickback Statute, 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7b(b);</FONT> the civil False Claims Act,
31 U.S.C. &#167;&#167; 3729 et seq.; the criminal False Claims Act, 42 U.S.C. <FONT STYLE="white-space:nowrap">1320a-7b(a);</FONT> any criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286, 287,
1347 and 1349, and the health care fraud criminal provisions under the Health Insurance Portability and Accountability Act of 1996, 42 U.S.C. &#167;&#167; 1320d et seq. (&#147;HIPAA&#148;); the Civil Monetary Penalties Law, 42 U.S.C. &#167;&#167; <FONT
STYLE="white-space:nowrap">1320a-7a</FONT> and <FONT STYLE="white-space:nowrap">1320a-7b;</FONT> the Physician Payments Sunshine Act, 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7h;</FONT> the Exclusion Statute, 42 U.S.C. &#167; <FONT
STYLE="white-space:nowrap">1320a-7;</FONT> HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, 42 U.S.C. &#167;&#167; 17921 et seq.; the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. &#167;&#167; 301 et
seq.; the regulations promulgated pursuant to such laws; and any similar federal, state and local laws and regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx) <I>Preclinical Studies and Clinical Trials</I>. (i)&nbsp;Except as
described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials conducted by or, to the knowledge of the Company, on behalf of or
sponsored by the Company, or in which the Company has participated that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or the results of which are referred to in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, as applicable, were, and if still pending are, being conducted in all material respects in accordance with all applicable Health Care Laws; (ii)&nbsp;the descriptions in the Registration Statement, the Pricing
Disclosure Package and the Prospectus of the results of such studies and trials are, to the knowledge of the Company, accurate and complete in all material respects and fairly present the data derived therefrom; (iii)&nbsp;the Company has no
knowledge of any other studies or trials not described in the Registration Statement, the Pricing Disclosure Package and the Prospectus the results of which are inconsistent with or which the Company reasonably believes call into question the
results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and (iv)&nbsp;the Company has not received any written notices or correspondence from the regulatory authorities or any other
governmental agency requiring or threatening the termination, modification or suspension of any <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or clinical trials that are described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus or the results of which are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus other than ordinary course communications with respect to modifications in connection with the design
and implementation of such studies or trials, and, to the Company&#146;s knowledge, there are no reasonable grounds for the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.
<U>Further Agreements of the Company</U>. The Company covenants and agrees with each Underwriter that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Required
Filings.</I> The Company will file the final Prospectus with the Commission within the time periods specified by Rule 424(b) and Rule 430A, 430B or 430C under the Securities Act, will file any Issuer Free Writing Prospectus to the extent required by
Rule 433 under the Securities Act; and the Company will file promptly all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the
Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus is required in connection with the offering or sale of the Securities; and the Company will furnish copies of the Prospectus and each Issuer Free
Writing Prospectus (to the extent not previously delivered) to the Underwriters in New York City prior to 10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in such quantities as the Representatives may
reasonably request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Delivery of Copies.</I> The Company will deliver, without charge, (i)&nbsp;to the
Representatives, two signed copies of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and documents incorporated by reference therein; and (ii)&nbsp;to each
Underwriter (A)&nbsp;a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B)&nbsp;during </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Prospectus Delivery Period (as defined below), as many copies of the Prospectus (including all amendments and supplements thereto and documents incorporated by reference therein and each
Issuer Free Writing Prospectus) as the Representatives may reasonably request. As used herein, the term &#147;Prospectus Delivery Period&#148; means such period of time after the first date of the public offering of the Securities as in the opinion
of counsel for the Underwriters a prospectus relating to the Securities is required by law to be delivered (or required to be delivered but for Rule 172 under the Securities Act) in connection with sales of the Securities by any Underwriter or
dealer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Amendments or Supplements, Issuer Free Writing Prospectuses.</I> Before making, preparing, using,
authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company will furnish to the
Representatives and counsel for the Underwriters a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement for review and will not make, prepare, use, authorize, approve, refer to or file any such Issuer Free Writing Prospectus
or file any such proposed amendment or supplement to which the Representatives reasonably object. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Notice to the
Representatives.</I> The Company will advise the Representatives promptly, and confirm such advice in writing (which may be by electronic mail), (i) when the Registration Statement has become effective; (ii)&nbsp;when any amendment to the
Registration Statement has been filed or becomes effective; (iii)&nbsp;when any supplement to the Pricing Disclosure Package, the Prospectus, any Issuer Free Writing Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or any amendment to the Prospectus has been filed or distributed; (iv)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment
or supplement to the Prospectus or the receipt of any comments from the Commission relating to the Registration Statement or any other request by the Commission for any additional information including, but not limited to, any request for
information concerning any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication; (v)&nbsp;of the issuance by the Commission or any other governmental or regulatory authority of any order
suspending the effectiveness of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package, the Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or the initiation or threatening of any proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act; (vi)&nbsp;of the occurrence of any event or
development within the Prospectus Delivery Period as a result of which the Prospectus, any of the Pricing Disclosure Package, any Issuer Free Writing Prospectus or any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in
order to make the statements therein, in the light of the circumstances existing when the Prospectus, the Pricing Disclosure Package, any such Issuer Free Writing Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication is delivered to a purchaser, not misleading; and (vii)&nbsp;of the receipt by the Company of any notice </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
with respect to any suspension of the qualification of the Securities for offer and sale in any jurisdiction or the initiation or, to the knowledge of the Company, threatening of any proceeding
for such purpose; and the Company will use its reasonable best efforts to prevent the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any Preliminary Prospectus, any of the
Pricing Disclosure Package or the Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or suspending any such qualification of the Securities and, if any such
order is issued, will obtain as soon as possible the withdrawal thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Ongoing Compliance.</I> (1)&nbsp;If during
the Prospectus Delivery Period (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any
material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Prospectus to comply
with law, the Company will as promptly as practicable notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission and furnish to the Underwriters and to such dealers as the Representatives
may designate such amendments or supplements to the Prospectus (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Prospectus as so amended or supplemented (or any
document to be filed with the Commission and incorporated by reference therein) will not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with law and
(2)&nbsp;if at any time prior to the Closing Date (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Pricing Disclosure Package as then amended or supplemented would include any untrue statement of a
material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading or (ii)&nbsp;it is
necessary to amend or supplement the Pricing Disclosure Package to comply with law, the Company will as promptly as practicable notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission
(to the extent required) and furnish to the Underwriters and to such dealers as the Representatives may designate such amendments or supplements to the Pricing Disclosure Package (or any document to be filed with the Commission and incorporated by
reference therein) as may be necessary so that the statements in the Pricing Disclosure Package as so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, be
misleading or so that the Pricing Disclosure Package will comply with law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Blue Sky Compliance.</I> The Company will qualify the Securities for
offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request and will continue such qualifications in effect so long as required for distribution of the Securities; <U>provided</U> that
the Company shall not be required to (i)&nbsp;qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii)&nbsp;file any general consent to
service of process in any such jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise so subject. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Earning Statement. </I>The Company will make generally available to its security holders and the Representatives as soon
as practicable an earning statement that satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder covering a period of at least twelve months beginning with the first fiscal quarter
of the Company occurring after the &#147;effective date&#148; (as defined in Rule 158) of the Registration Statement; provided that the Company will be deemed to have furnished such statements to its security holders and the Representatives to the
extent they are filed on the Commission&#146;s Electronic Data Gathering, Analysis, and Retrieval System (&#147;EDGAR&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Clear Market.</I> For a period of 60 days after the date of the Prospectus (the &#147;Restricted Period&#148;), the
Company will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or
indirectly, or submit to, or file with, the Commission a registration statement under the Securities Act relating to, any shares of Stock or any securities convertible into or exercisable or exchangeable for Stock, or publicly disclose the intention
to undertake any of the foregoing, or (ii)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock or any such other securities, whether any such transaction
described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Stock or such other securities, in cash or otherwise, without the prior written consent of Jefferies LLC and TD Securities (USA) LLC, other than the Securities to be sold
hereunder and the delivery of Warrant Shares upon exercise of the Warrants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:9%; font-size:10pt; font-family:Times New Roman">The restrictions described above do not apply
to (i)&nbsp;the issuance of shares of Stock or securities convertible into or exercisable for shares of Stock pursuant to the conversion or exchange of convertible or exchangeable securities or the exercise of
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, warrants or options (including net exercise) or the settlement of RSUs (including net settlement), in each case outstanding on the date of this Agreement and described in the Prospectus;
(ii)&nbsp;grants of stock options, stock awards, restricted stock, RSUs, or other equity awards and the issuance of shares of Stock or securities convertible into or exercisable or exchangeable for shares of Stock (whether upon the exercise of stock
options or otherwise) to the Company&#146;s employees, officers, directors, advisors, or consultants pursuant to the terms of an equity compensation plan in effect as of the Closing Date and described in the Prospectus; (iii)&nbsp;the sale or
issuance of or entry into an agreement to sell or issue up to 10% of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
outstanding shares of Stock, or securities convertible into, exercisable for, or which are otherwise exchangeable for, Stock, immediately following the Closing Date, in connection with the
Company&#146;s acquisition of one or more businesses, products, assets or technologies (whether by means of merger, stock purchase, asset purchase or otherwise) or in connection with joint ventures, collaboration or licensing agreements, marketing
or distribution arrangements, commercial relationships or other strategic transactions, provided that such recipients enter into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the Underwriters; or (iv)&nbsp;the filing of any
registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> relating to securities granted or to be granted pursuant to any plan in effect on the date of this Agreement and described in the Prospectus or any assumed benefit plan
pursuant to an acquisition or similar strategic transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Use of Proceeds.</I> The Company will apply the net
proceeds from the sale of the Securities as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#147;Use of Proceeds&#148;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>No Stabilization.</I> Neither the Company nor its subsidiaries or affiliates will take, directly or indirectly, without
giving effect to activities by the Underwriters, any action designed to or that would reasonably be expected to cause or result in any stabilization or manipulation of the price of the Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Exchange Listing.</I> The Company will use its reasonable best efforts to list for quotation the Underwritten Shares,
the Option Shares and the Warrant Shares on the Nasdaq Global Select Market (the &#147;Nasdaq Market&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)
<I>Reports.</I> So long as the Securities or the Warrant Shares are outstanding, the Company will furnish to the Representatives, as soon as commercially reasonable after the date that they are available, copies of all reports or other
communications (financial or other) furnished to holders of the Securities or the Warrant Shares, and copies of any reports and financial statements furnished to or filed with the Commission or any national securities exchange or automatic quotation
system; <U>provided</U> the Company will be deemed to have furnished such reports and financial statements to the Representatives to the extent they are filed on EDGAR, or any successor to such system. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Record Retention</I>. The Company will, pursuant to reasonable procedures developed in good faith, retain copies of each
Issuer Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Shelf Renewal</I>. If immediately prior to the third anniversary (the &#147;Renewal Deadline&#148;) on the initial
effective date of the Registration Statement, any of the Securities remain unsold by the Underwriters, the Company will, prior to the Renewal Deadline, file, if it has not already done so and is eligible to do so, a new automatic shelf registration
statement relating to the Securities, in a form </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
satisfactory to the Representatives. If the Company is not eligible to file an automatic shelf registration statement, the Company will, prior to the Renewal Deadline, if it has not already done
so, file a new shelf registration statement relating to the Shares, in a form satisfactory to the Representatives, and will use its best efforts to cause such registration statement to be declared effective within 180 days after the Renewal
Deadline. The Company will take all other action necessary or appropriate to permit the issuance and sale of the Securities to continue as contemplated in the expired registration statement relating to the Securities. References herein to the
Registration Statement shall include such new automatic shelf registration statement or such new shelf registration statement, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>Emerging Growth Company</I>. The Company will promptly notify the Representatives if the Company ceases to be an
Emerging Growth Company at any time prior to the later of (i)&nbsp;completion of the distribution of Securities within the meaning of the Securities Act and (ii)&nbsp;completion of the <FONT STYLE="white-space:nowrap">60-day</FONT> Restricted Period
referred to in Section&nbsp;4(h) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I>Warrant Shares Reserved</I>. The Company shall, at all times while any
Warrants are outstanding, reserve and keep available out of its authorized but unissued and otherwise unreserved shares of common stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of such Warrants, the number of
Warrant Shares that are initially issuable and deliverable upon the exercise of the then-outstanding Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Certain Agreements
of the Underwriters</U>. Each Underwriter hereby represents and agrees that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) It has not, and will not use, authorize
use of, refer to or participate in the planning for use of, any &#147;free writing prospectus&#148;, as defined in Rule 405 under the Securities Act (which term includes use of any written information furnished to the Commission by the Company and
not incorporated by reference into the Registration Statement and any press release issued by the Company) other than (i)&nbsp;a free writing prospectus that contains no &#147;issuer information&#148; (as defined in Rule 433(h)(2) under the
Securities Act) that was not included (including through incorporation by reference) in the Preliminary Prospectus or a previously filed Issuer Free Writing Prospectus, (ii)&nbsp;any Issuer Free Writing Prospectus listed on Annex A or prepared
pursuant to Section&nbsp;3(c) or Section&nbsp;4(c) above (including any electronic road show), or (iii)&nbsp;any free writing prospectus prepared by such Underwriter and approved by the Company in advance in writing (each such free writing
prospectus referred to in clauses (i)&nbsp;or (iii), an &#147;Underwriter Free Writing Prospectus&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) It has not
and will not, without the prior written consent of the Company, use any free writing prospectus that contains the final terms of the Securities unless such terms have previously been included in a free writing prospectus filed with the Commission;
<I>provided</I> that Underwriters may use a term sheet substantially in the form of Annex C hereto without the consent of the Company; <I>provided further</I> that any Underwriter using such term sheet shall notify the Company, and provide a copy of
such term sheet to the Company, prior to, or substantially concurrently with, the first use of such term sheet. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) It is not subject to any pending proceeding under Section&nbsp;8A of the
Securities Act with respect to the offering (and will promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery Period). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Conditions of Underwriters&#146; Obligations.</U> The obligation of each Underwriter to purchase the Securities on the Closing Date or
on the Additional Closing Date, as the case may be, as provided herein is subject to the performance by the Company of its covenants and other obligations hereunder and to the following additional conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Registration Compliance; No Stop Order.</I> No order suspending the effectiveness of the Registration Statement shall be
in effect, and no proceeding for such purpose or pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been timely filed with
the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance with Section&nbsp;4(a) hereof; and all requests by the Commission for
additional information shall have been complied with to the reasonable satisfaction of the Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<I>Representations and Warranties.</I> The representations and warranties of the Company contained herein shall be true and correct on the date hereof and on and as of the Closing Date or the Additional Closing Date, as the case may be; and the
statements of the Company and its officers made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date or the Additional Closing Date, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>No Material Adverse Change.</I> No event or condition of a type described in Section&nbsp;3(i) hereof shall have
occurred or shall exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement thereto) and the Prospectus (excluding any amendment or supplement thereto) and the effect of which in the
judgment of the Representatives makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner
contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Officers&#146; Certificate.</I> The Representatives shall have
received on and as of the Closing Date or the Additional Closing Date, as the case may be, a certificate of the chief financial officer or chief accounting officer of the Company and one additional senior executive officer of the Company who is
satisfactory to the Representatives on behalf of the Company and not in their individual capacities (i)&nbsp;confirming that such officers have carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus and, to
the knowledge of such officers, the representations set forth in Sections 3(b) and 3(f) hereof are true and correct, (ii)&nbsp;confirming that the other representations and warranties of the Company in this Agreement are true and correct and that
the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date or the Additional Closing Date, as the case may be, and (iii)&nbsp;to the effect set forth
in paragraphs (a), (b) and (c)&nbsp;above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Comfort Letters.</I> On the date of this Agreement and on the Closing
Date or the Additional Closing Date, as the case may be, Ernst&nbsp;&amp; Young LLP shall have furnished to the Representatives, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the
Underwriters, in form and substance reasonably satisfactory to the Representatives, containing statements and information of the type customarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial
statements and certain financial information contained or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided, that the letter delivered on the Closing Date or the Additional
Closing Date, as the case may be, shall use a <FONT STYLE="white-space:nowrap">&#147;cut-off&#148;</FONT> date no more than two business days prior to such Closing Date or such Additional Closing Date, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Counsel for the Company.</I> Wilmer Cutler
Pickering Hale and Dorr LLP, counsel for the Company, shall have furnished to the Representatives, at the request of the Company, their written opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement, dated the Closing Date or the
Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Opinion of Intellectual Property Counsel for the Company</I>. The Representatives shall have received an opinion, on and
as of the Closing Date or the Additional Closing Date, as the case may be, of Cooley LLP, intellectual property counsel for the Company, addressed to the Underwriters and in form and substance satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Counsel for the Underwriters.</I> The
Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, an opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement, addressed to the Underwriters, of Davis Polk&nbsp;&amp;
Wardwell LLP, counsel for the Underwriters, with respect to such matters as the Representatives may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon
such matters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>No Legal Impediment to Issuance and Sale.</I> No action shall have
been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date or the Additional Closing Date, as the case may
be, prevent the issuance or sale of the Securities; and no injunction or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance
or sale of the Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Good Standing</I>. The Representatives shall have received on and as of the Closing Date
or the Additional Closing Date, as the case may be, satisfactory evidence of the good standing of the Company and its significant subsidiaries in their respective jurisdictions of organization and their good standing in such other jurisdictions as
the Representatives may reasonably request, in each case in writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions. Notwithstanding the above, the Representatives agree and acknowledge
that, to the extent requested, satisfactory evidence of good standing may not be readily, or entirely, available with respect to the Company&#146;s significant subsidiaries organized in the P.R.C. and the Company shall not be required to provide
such evidence unless requested at least 10 business days prior to the Closing Date or the Additional Closing Date, as applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Exchange Listing.</I> The Underwritten Shares and Option Shares to be delivered on the Closing Date or the Additional
Closing Date, as the case may be, and any Warrant Shares to be delivered upon exercise of the Warrants shall have been approved for listing on the Nasdaq Market, subject to official notice of issuance. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements</I>. The
<FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, each substantially in the form of Exhibit A hereto, between you and certain officers and directors of the Company relating to sales and certain other dispositions of shares of
Stock or certain other securities, delivered to you on or before the date hereof, shall be in full force and effect on the Closing Date or the Additional Closing Date, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Additional Documents.</I> On or prior to the Closing Date or the Additional Closing Date, as the case may be, the
Company shall have furnished to the Representatives such further certificates and documents as the Representatives may reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Form of Warrant</I>. On or prior to the Closing Date, the Representatives shall have received a form of Warrant in form
and substance reasonably satisfactory to the Representatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All opinions, letters, certificates and evidence mentioned above or elsewhere in this
Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Indemnification and Contribution</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Indemnification of the Underwriters.</I> The Company agrees to indemnify and hold harmless each Underwriter, its affiliates, directors
and officers and each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, from and against any and all losses, claims, damages and liabilities (including,
without limitation, legal fees and other expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred), joint or several, that arise out of, or are based upon, (i)&nbsp;any untrue
statement or alleged untrue statement of a material fact contained or incorporated by reference in the Registration Statement or caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary
in order to make the statements therein, not misleading, or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained or incorporated by reference in the Prospectus (or any amendment or supplement thereto), any
Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) under the Securities Act, any Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any road show as defined in Rule 433(h) under the Securities Act (a &#147;road show&#148;) or any Pricing Disclosure Package (including any Pricing Disclosure Package that
has subsequently been amended), or caused by any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, in each case
except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to any
Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that the only such information furnished by any Underwriter consists of the information
described as such in paragraph (b)&nbsp;below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Indemnification of the Company.</I> Each Underwriter agrees, severally and not
jointly, to indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20
of the Exchange Act to the same extent as the indemnity set forth in paragraph (a)&nbsp;above, but only with respect to any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue statement or omission or alleged
untrue statement or omission made in reliance upon and in conformity with any information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration
Statement, the Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication, any road show or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), it being </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
understood and agreed upon that the only such information furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter: the
concession figure appearing in the third paragraph under the caption &#147;Underwriting&#148;, and the information contained in the sixteenth, seventeenth and eighteenth paragraphs under the caption &#147;Underwriting&#148;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Notice and Procedures.</I> If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand
shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs of this Section&nbsp;7, such person (the &#147;Indemnified Person&#148;) shall promptly notify the person against
whom such indemnification may be sought (the &#147;Indemnifying Person&#148;) in writing; <U>provided</U> that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have under the preceding paragraphs of
this Section&nbsp;7 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and <U>provided</U>, <U>further</U>, that the failure to notify the Indemnifying Person shall
not relieve it from any liability that it may have to an Indemnified Person otherwise than under the preceding paragraphs of this Section&nbsp;7. If any such proceeding shall be brought or asserted against an Indemnified Person and it shall have
notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person, be counsel to the Indemnifying Person) to
represent the Indemnified Person and any others entitled to indemnification pursuant to this Section that the Indemnifying Person may designate in such proceeding and shall pay the reasonable fees and expenses in such proceeding and shall pay the
reasonable fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of
such Indemnified Person unless (i)&nbsp;the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii)&nbsp;the Indemnifying Person has failed within a reasonable time to retain counsel reasonably satisfactory to
the Indemnified Person; (iii)&nbsp;the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the Indemnifying Person; or (iv)&nbsp;the named
parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel would be inappropriate due to actual or potential differing
interests between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in
addition to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid or reimbursed as they are incurred. Any such separate firm for any Underwriter, its affiliates, directors and officers and any control
persons of such Underwriter shall be designated in writing by the Representatives and any such separate firm for the Company, its directors, its officers who signed the Registration Statement and any control persons of the Company shall be
designated in writing by the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent, the Indemnifying Person agrees to indemnify each
Indemnified Person from and against any loss or liability by reason of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
settlement. Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for fees and expenses of
counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by the
Indemnifying Person of such request and (ii)&nbsp;the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request prior to the date of such settlement. No Indemnifying Person shall, without the written
consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have been sought hereunder by such Indemnified
Person, unless such settlement (x)&nbsp;includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of such
proceeding and (y)&nbsp;does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Contribution.</I> If the indemnification provided for in paragraphs (a)&nbsp;or (b) above is unavailable to an Indemnified Person or
insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable
by such Indemnified Person as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters on the other, from
the offering of the Securities or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;but also the
relative fault of the Company, on the one hand, and the Underwriters on the other, in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations.
The relative benefits received by the Company, on the one hand, and the Underwriters on the other, shall be deemed to be in the same respective proportions as the net proceeds (before deducting expenses) received by the Company from the sale of the
Securities and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate offering price of the Securities. The
relative fault of the Company, on the one hand, and the Underwriters on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to
state a material fact relates to information supplied by the Company or by the Underwriters and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Limitation on Liability.</I> The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to
paragraph (d)&nbsp;above were determined by <U>pro</U> <U>rata</U> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable considerations
referred to in paragraph (d)&nbsp;above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to in paragraph (d)&nbsp;above shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such Indemnified Person in connection
with any such action or claim. Notwithstanding the provisions of paragraphs (d)&nbsp;and (e), in no event shall an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions
received by such Underwriter with respect to the offering of the Securities exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged
omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The
Underwriters&#146; obligations to contribute pursuant to paragraphs (d)&nbsp;and (e) are several in proportion to their respective purchase obligations hereunder and not joint. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Remedies.</I> The remedies provided for in this Section&nbsp;7 paragraphs
(a)&nbsp;through (e) are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Effectiveness of Agreement</U>. This Agreement shall become effective as of the date first written above. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Termination</U>. This Agreement may be terminated in the absolute discretion of the Representatives, by notice to the Company, if after
the execution and delivery of this Agreement and on or prior to the Closing Date or, in the case of the Option Shares, prior to the Additional Closing Date (i)&nbsp;trading generally shall have been suspended or materially limited on or by any of
the New York Stock Exchange or The Nasdaq Stock Market; (ii)&nbsp;trading of any securities issued or guaranteed by the Company shall have been suspended on any exchange or in any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; (iii)&nbsp;a general moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or
(iv)&nbsp;there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States, that, in the judgment of the Representatives, is material and
adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the Closing Date or Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the
Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Defaulting Underwriter</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If, on the Closing Date or the Additional Closing Date, as the case may be, any Underwriter defaults on its obligation to purchase the
Securities that it has agreed to purchase hereunder on such date, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters may in their discretion arrange for the purchase of such Securities by other persons satisfactory to the
Company on the terms contained in this Agreement. If, within 36 hours after any such default by any Underwriter, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters do not arrange for the purchase of such Securities, then the
Company shall be entitled to a further period of 36 hours within which to procure other persons satisfactory to the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchase such Securities on such terms. If other persons become obligated or agree to purchase the Securities of a defaulting Underwriter, either the
<FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters or the Company may postpone the Closing Date or the Additional Closing Date, as the case may be, for up to five full business days in order to effect any changes that in the opinion
of counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or arrangement, and the Company agrees to promptly prepare any amendment or supplement to the
Registration Statement and the Prospectus that effects any such changes. As used in this Agreement, the term &#147;Underwriter&#148; includes, for all purposes of this Agreement unless the context otherwise requires, any person not listed in
Schedule 1 hereto that, pursuant to this Section&nbsp;10, purchases Securities that a defaulting Underwriter agreed but failed to purchase. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If, after giving effect to any arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Securities that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be,
does not exceed <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of Securities to be purchased on such date, then the Company shall have the right to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT>
Underwriter to purchase the number of Securities that such Underwriter agreed to purchase hereunder on such date plus such Underwriter&#146;s pro rata share (based on the number of Securities that such Underwriter agreed to purchase on such date) of
the Securities of such defaulting Underwriter or Underwriters for which such arrangements have not been made. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If, after giving effect
to any arrangements for the purchase of the Securities of a defaulting Underwriter or Underwriters by the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate
number of Securities that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be, exceeds <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate amount of Securities to be purchased on such date, or
if the Company shall not exercise the right described in paragraph (b)&nbsp;above, then this Agreement or, with respect to any Additional Closing Date, the obligation of the Underwriters to purchase Option Shares on the Additional Closing Date, as
the case may be, shall terminate without liability on the part of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters. Any termination of this Agreement pursuant to this Section&nbsp;10 shall be without liability on the part of
the Company, except that the Company will continue to be liable for the payment of expenses as set forth in Section&nbsp;11 hereof and except that the provisions of Section&nbsp;7 hereof shall not terminate and shall remain in effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Nothing contained herein shall relieve a defaulting Underwriter of any liability it may have to the Company or any <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter for damages caused by its default. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Payment of Expenses</U><I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company will pay or
cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i)&nbsp;the costs incident to the authorization, issuance, sale, preparation and delivery of the Securities and any
taxes payable in that connection; (ii)&nbsp;the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement, the Preliminary Prospectus, any Issuer Free Writing Prospectus, any Pricing Disclosure
Package and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii)&nbsp;the fees and expenses of the Company&#146;s counsel and independent accountants; (iv)&nbsp;the fees and expenses
incurred in connection with the registration or qualification and determination of eligibility for investment of the Securities under the laws of such jurisdictions as the Representatives may designate and the preparation, printing and distribution
of a Blue Sky Memorandum (including the related fees and expenses of counsel for the Underwriters);&nbsp;(v) the cost of preparing stock certificates; (vi)&nbsp;the costs and charges of any transfer agent and any registrar; (vii)&nbsp;all expenses
incurred by the Company in connection with any &#147;road show&#148; presentation to potential investors and (viii)&nbsp;all fees and expenses related to the listing of the Underwritten Shares, Option Shares and Warrant Shares on the Nasdaq Market;
provided that the aggregate amount payable by the Company pursuant to clause (iv)&nbsp;shall not exceed $25,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If (i)&nbsp;this
Agreement is terminated pursuant to Section&nbsp;9, (ii) the Company for any reason fails to tender the Securities for delivery to the Underwriters or (iii)&nbsp;the Underwriters decline to purchase the Securities for any reason permitted under this
Agreement, the Company agrees to reimburse the Underwriters for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including the fees and expenses of their counsel) reasonably
incurred by the Underwriters in connection with this Agreement and the offering contemplated hereby. For the avoidance of doubt, it is understood that the Company shall not pay or reimburse any costs, fees or expenses incurred by any Underwriter
that defaults on its obligations to purchase the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Persons Entitled to Benefit of Agreement</U>. This Agreement shall
inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Underwriter referred to in Section&nbsp;7
hereof. Nothing in this Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Securities from any
Underwriter shall be deemed to be a successor merely by reason of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Survival</U>. The respective indemnities, rights
of contribution, representations, warranties and agreements of the Company and the Underwriters contained in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant
hereto shall survive the delivery of and payment for the Securities and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Underwriters or the
directors, officers, controlling persons or affiliates referred to in Section&nbsp;7 hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Certain Defined Terms</U>. For purposes of this Agreement, (a)&nbsp;except where
otherwise expressly provided, the term &#147;affiliate&#148; has the meaning set forth in Rule 405 under the Securities Act; (b)&nbsp;the term &#147;business day&#148; means any day other than a day on which banks are permitted or required to be
closed in New York City; and (c)&nbsp;the term &#147;subsidiary&#148; has the meaning set forth in Rule 405 under the Securities Act; and (d)&nbsp;the term &#147;significant subsidiary&#148; has the meaning set forth in Rule <FONT
STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.
<U>Compliance with USA Patriot Act</U>. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Underwriters are required to
obtain, verify and record information that identifies their respective clients, including the Company, which information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to
properly identify their respective clients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Notices</I>. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed
or transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be given to the Representatives c/o Jefferies LLC, 520 Madison Avenue, New York, New York 10022, Attention: General Counsel, and TD Securities
(USA) LLC, 1 Vanderbilt Avenue, 11th Floor, New York, New York 10017, Attention: Head of Equity Capital Markets; General Counsel. Notices to the Company shall be given to it at Terns Pharmaceuticals, Inc., 1065 East Hillsdale, Suite 100, Attention:
Chief Executive Officer and General Counsel, and a copy (which shall not constitute notice) to Wilmer Cutler Pickering Hale and Dorr LLP, 250 Greenwich Street, New York, New York 10007. Attention: Brian Johnson. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Governing Law.</I> This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by
and construed in accordance with the laws of the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Waiver of Jury Trial.</I> Each of the parties hereto hereby
waives any right to trial by jury in any suit or proceeding arising out of or relating to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Recognition of the U.S.
Special Resolution Regimes</I>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In the event that any Underwriter that is a Covered Entity becomes subject to a
proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the
U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In the event that any Underwriter that is a Covered Entity or a BHC Act
Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such
Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">As used in this Section&nbsp;16(g): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;BHC Act Affiliate&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted in accordance with, 12
U.S.C. &#167; 1841(k). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;Covered Entity&#148; means any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">(i) a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">(ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">(iii) a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;Default Right&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167;
252.81, 47.2 or 382.1, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;U.S. Special Resolution Regime&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act
and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Counterparts.</I> This Agreement may be signed in counterparts (which may include counterparts delivered by any standard form of
telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument. The words &#147;execution,&#148; &#147;signed,&#148; &#147;signature,&#148; and words of like import in this Agreement or
in any other certificate, agreement or document related to this Agreement, if any, shall include images of manually executed signatures transmitted by facsimile or other electronic format (including, without limitation, &#147;pdf,&#148;
&#147;tif&#148; or &#147;jpg&#148;) and other electronic signatures (including, without limitation, DocuSign and AdobeSign). The use of electronic signatures and electronic records (including, without limitation, any contract or other record
created, generated, sent, communicated, received, or stored by electronic means) shall be of the same legal effect, validity and enforceability as a manually executed signature or use of a paper-based record-keeping system to the fullest extent
permitted by applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act and any other applicable law, including, without limitation, any state law based
on the Uniform Electronic Transactions Act or the Uniform Commercial Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Amendments or Waivers.</I> No amendment or waiver of any provision of this Agreement,
nor any consent or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Headings.</I> The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the
meaning or interpretation of, this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Pages Follow</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please indicate your acceptance
of this Agreement by signing in the space provided below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">TERNS PHARMACEUTICALS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Vignola</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Mark Vignola</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Chief Financial Officer</TD></TR></TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted: As of the date first written above</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">JEFFERIES LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">TD SECURITIES (USA) LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">For themselves and on behalf of the</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">several Underwriters listed</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">in Schedule 1 hereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">JEFFERIES LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Matthew Kim</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Matthew Kim</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">TD SECURITIES (USA) LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Bill Follis</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Bill Follis</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule 1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,290,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">857,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TD Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,396,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">678,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BMO Capital Markets Corp.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,191,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">238,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">UBS Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,191,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">238,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citizens JMP Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">923,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">184,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mizuho Securities USA LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">923,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">184,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,919,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,380,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex A </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pricing Disclosure Package</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Free Writing Prospectus containing Form of Warrant attached hereto as Exhibit&nbsp;B. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pricing Information Provided Orally by Underwriters</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Underwritten Shares: 11,919,048 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Option Shares: 2,145,000 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Public Offering Price Per Share: $10.50 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Warrants: 2,380,952 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Public Offering Price Per Warrant: $10.4999 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of shares and warrants to be issued may be reallocated among shares or warrants such that the
aggregate number of shares and warrants issued does not exceed 14,300,000. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Exercise Price for the Warrants: $0.0001 </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex C </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Terns Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Pricing Term Sheet </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">None.<B> </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">September [&#149;], 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TD Securities (USA) LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the several Underwriters listed in </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule 1 to the
Underwriting </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agreement referred to below </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o TD Securities (USA) LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 Vanderbilt Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Re: Terns
Pharmaceuticals, Inc. &#151; Public Offering </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that you, each as one of several representatives (the &#147;Representatives&#148;) of the several Underwriters,
propose to enter into an underwriting agreement (the &#147;Underwriting Agreement&#148;) with Terns Pharmaceuticals, Inc., a Delaware corporation (the &#147;Company&#148;), providing for the public offering (the &#147;Public Offering&#148;) by the
several Underwriters named in Schedule 1 to the Underwriting Agreement (the &#147;Underwriters&#148;), of common stock, par value $0.0001 per share (&#147;Common Stock&#148;), of the Company and <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants to purchase shares of common stock of the Company (the &#147;Securities&#148;). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that there are no additional Underwriters other than you listed on Schedule 1 to the Underwriting Agreement, all references to
the Representatives and the Underwriters shall refer to you, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires. To the extent only one Representative is listed above, all references to
the term Representatives shall mean Representative in the singular form. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the Underwriters&#146; agreement to purchase and make the Public
Offering of the Securities, and for other good and valuable consideration, the receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent of the Representatives on behalf of the Underwriters, the
undersigned will not, and will not cause any direct or indirect affiliate to, during the period beginning on the date of this letter agreement (this &#147;Letter Agreement&#148;) and ending at the close of business 60 days after the date of the
final prospectus relating to the Public Offering (the &#147;Prospectus&#148;) (such period, the &#147;Restricted Period&#148;), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to
sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock (including without
limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise
of a stock option or warrant) (collectively with the Common Stock, <FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Securities&#148;), (2) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any
of the economic consequences of ownership of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such transaction described in clause (1)&nbsp;or (2) above is to be settled by delivery of
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, in cash or otherwise, (3)&nbsp;make any demand for or exercise any right with respect to the registration of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, or
(4)&nbsp;publicly disclose the intention to do any of the foregoing. The undersigned acknowledges and agrees that the foregoing precludes the undersigned from engaging in any hedging or other transactions or arrangements (including, without
limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could
reasonably be expected to lead to or result in, a sale or disposition or transfer (whether by the undersigned or any other person) of any economic consequences of ownership, in whole or in part, directly or indirectly, of any <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, in cash or
otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the undersigned may: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) transfer or dispose of the undersigned&#146;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) as a bona fide gift or gifts, or for bona fide estate planning purposes, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) by will, other testamentary document or intestacy, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned, or if the undersigned is
a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust (for purposes of this Letter Agreement, &#147;immediate family&#148; shall mean any relationship by blood, current or former marriage, domestic
partnership or adoption, not more remote than first cousin), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) to a partnership, limited liability company or other entity of which
the undersigned and the immediate family of the undersigned are the legal and beneficial owner of all of the outstanding equity securities or similar interests, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) to a nominee or custodian of a person or entity to whom a disposition or transfer would
be permissible under clauses (i)&nbsp;through (iv) above, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;if the undersigned is a corporation, partnership, limited liability
company, trust or other business entity, (A)&nbsp;to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended)
of the undersigned, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control with the undersigned or affiliates of the undersigned (including, for the avoidance of doubt, where the
undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B)&nbsp;as part of a distribution to members, partners, shareholders or other equity holders of the
undersigned, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree, separation
agreement or other court order, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) to the Company from an employee or other service provider of the Company upon death, disability or
termination of employment or service, in each case, of such employee or service provider, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix) as part of a sale of the undersigned&#146;s
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities acquired (A)&nbsp;in open market transactions after the closing date for the Public Offering or (B)&nbsp;from the Underwriters in the Public Offering, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(x) to the Company in connection with the vesting, settlement, or exercise of restricted stock units, options, warrants or other rights to
purchase shares of Common Stock (including, in each case, by way of &#147;net&#148; or &#147;cashless&#148; exercise), including for the payment of exercise price and tax and remittance payments due as a result of the vesting, settlement, or
exercise of such restricted stock units, options, warrants or rights, provided that any such shares of Common Stock received upon such exercise, vesting or settlement shall be subject to the terms of this Letter Agreement, and provided further that
any such restricted stock units, options, warrants or rights are held by the undersigned pursuant to an agreement or equity awards granted under a stock incentive plan or other equity award plan, each such agreement or plan which is described in the
Registration Statement, the Pricing Disclosure Package and the Prospectus, or filed as an exhibit to the Registration Statement, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(xi)
pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by the Board of Directors of the Company and made to all holders of the Company&#146;s capital stock involving a Change of Control
(as defined below) of the Company (for purposes hereof, &#147;Change of Control&#148; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a
person or group of affiliated persons, of shares of capital stock if, after such transfer, such person or group of affiliated persons would hold more than 50% of the outstanding voting securities of the Company (or the surviving entity));
<U>provided</U> that in the event that such tender offer, merger, consolidation or other similar transaction is not completed, the undersigned&#146;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities shall remain subject to the provisions
of this Letter Agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U> that (A)&nbsp;in the case of any transfer, distribution or other disposition pursuant to
clause (a)(i), (ii), (iii), (iv), (v), (vi) and (vii), such transfer shall not involve a disposition for value and each donee, devisee, transferee or distributee shall execute and deliver to the Representatives a
<FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of this Letter Agreement, (B)&nbsp;in the case of any transfer, distribution or disposition pursuant to clauses (a)(ii), (iii), (iv), (v), (vi), and (x), no filing by any party
(devisee, transferor, transferee, distributer or distributee) under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or other public announcement shall be required or shall be made voluntarily in connection with such
transfer or distribution (other than a filing on a Form 5 made after the expiration of the Restricted Period referred to above) and (C)&nbsp;in the case of any transfer or distribution pursuant to clauses (a)(vii) and (viii)&nbsp;it shall be a
condition to such transfer that no public filing, report or announcement shall be voluntarily made and if any filing under Section&nbsp;16(a) of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial
ownership of shares of Common Stock in connection with such transfer or distribution shall be legally required during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and
conditions of such transfer; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) exercise outstanding options, settle restricted stock units or other equity awards or exercise warrants
pursuant to plans described in the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided that any <FONT STYLE="white-space:nowrap">Lock-up</FONT> Securities received upon such exercise, vesting or settlement shall be
subject to the terms of this Letter Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) convert outstanding preferred stock, <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants to acquire Common Stock, warrants to acquire preferred stock or convertible securities into shares of Common Stock or warrants to acquire shares of Common Stock; provided that any such shares of Common Stock or warrants received upon such
conversion shall be subject to the terms of this Letter Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) establish or amend existing trading plans pursuant to Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer or disposition of shares of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities; <U>provided</U> that (1)&nbsp;such plans do not provide for the transfer or
disposition of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities during the Restricted Period and (2)&nbsp;no filing by any party under the Exchange Act or other public announcement shall be required or made voluntarily in connection with
such trading plan during the Restricted Period in contravention of this <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)
sell <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities under existing trading plans pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act; provided that any filing, report or announcement shall clearly
indicate in the footnotes thereto the nature and conditions of such transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the undersigned is not a natural person, the undersigned
represents and warrants that no single natural person, entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d)(3) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;)) beneficially owns, directly or
indirectly, 50% or more of the common equity interests, or 50% or more of the voting power, in the undersigned. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In furtherance of the foregoing, the Company, and any duly appointed transfer agent for the
registration or transfer of the securities described herein, are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Letter Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Letter Agreement. All
authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the
Underwriters solicited any action from the undersigned with respect to the Public Offering of the Securities and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate. The
undersigned further acknowledges and agrees that, although the Representatives may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with the Public Offering, the Representatives and the
other Underwriters are not making a recommendation to you to enter into this Letter Agreement, and nothing set forth in such disclosures is intended to suggest that the Representatives or any Underwriter is making such a recommendation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that, if either (i)&nbsp;the Representatives, on the one hand, or the Company, on the other hand, informs the
other, prior to the execution of the Underwriting Agreement, that it has determined not to proceed with the Public Offering, (ii)&nbsp;the Registration Statement is withdrawn, prior to the execution of the Underwriting Agreement, (iii)&nbsp;the
Underwriting Agreement does not become effective by September&nbsp;30, 2024, (iv) the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the
Common Stock to be sold thereunder, or (v)&nbsp;the Restricted Period has expired, this Letter Agreement shall automatically terminate and be of no further force and effect and the undersigned shall be released from all obligations under this Letter
Agreement. The undersigned understands that the Underwriters are entering into the Underwriting Agreement and proceeding with the Public Offering in reliance upon this Letter Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Letter Agreement and any claim, controversy or dispute arising under or related to this
Letter Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to conflict of law principles thereof. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit B </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERNS PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT TO PURCHASE COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Number of Shares: [_________] </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">(subject to adjustment) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrant No. [___]
&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;Original Issue Date: September [___], 2024 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Terns Pharmaceuticals, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), hereby certifies that, for good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, [___________] or its registered assigns (the &#147;<B>Holder</B>&#148;) is entitled, subject to the terms set forth below, to purchase from the Company up to a total of
[______] shares of common stock, $0.0001 par value per share (the &#147;<B>Common Stock</B>&#148;), of the Company (each such share, a &#147;<B>Warrant Share</B>&#148; and all such shares, the &#147;<B>Warrant Shares</B>&#148;) at an exercise price
per share equal to $0.0001 per share (as adjusted from time to time as provided in Section&nbsp;9 herein, the &#147;<B>Exercise Price</B>&#148;) upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock
issued in exchange, transfer or replacement hereof, the &#147;<B>Warrant</B>&#148;) at any time and from time to time on or after the date hereof (the &#147;<B>Original Issue Date</B>&#148;), subject to the following terms and conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <I>Definitions</I>. For purposes of this Warrant, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Affiliate</B>&#148; means any Person directly or indirectly controlled by, controlling or under common control with, a Holder, as
such terms are used in and construed under Rule 405 under the Securities Act, but only for so long as such control shall continue. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
&#147;<B>Commission</B>&#148; means the United States Securities and Exchange Commission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Closing Sale Price</B>&#148; means,
for any security as of any date, the last trade price for such security on the Principal Trading Market for such security, as reported by Bloomberg L.P., or, if such Principal Trading Market begins to operate on an extended hours basis and does not
designate the last trade price, then the last trade price of such security prior to 4:00 P.M., New York City time, as reported by Bloomberg L.P., or if the security is not listed for trading on a national securities exchange or other trading market
on the relevant date, the last quoted bid price for the security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the relevant date as reported by OTC Markets Group Inc. (or a similar
organization or agency succeeding to its functions of reporting prices). If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be
the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then the Board of Directors of the Company shall use its good faith judgment
to determine the fair market value. The Board of Directors&#146; determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock
combination or other similar transaction during the applicable calculation period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Marketable Securities</B>&#148; means securities meeting all of the following
requirements: (i)&nbsp;the issuer thereof is then subject to the reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), and is then current in its
filing of all required reports and other information under the Securities Act and the Exchange Act; (ii)&nbsp;the class and series of shares or other security of the issuer that would be received by Holder in connection with the Fundamental
Transaction (as defined below) were Holder to exercise this Warrant on or prior to the closing thereof is then traded or quoted on a nationally recognized securities exchange, inter-dealer </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">quotation system or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, and (iii)&nbsp;following the
closing of such Fundamental Transaction, the Holder would not be restricted from publicly <FONT STYLE="white-space:nowrap">re-selling</FONT> all of the issuer&#146;s shares and/or other securities that would be received by the Holder in such
Fundamental Transaction were the Holder to exercise or convert this Warrant in full on or prior to the closing of such Fundamental Transaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Principal Trading Market</B>&#148; means the national securities exchange or other trading market on which the Common Stock is
primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Select Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)
&#147;<B>Registration Statement</B>&#148; means the Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-</FONT> 269508), that became effective on
February&nbsp;10, 2023. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B>Trading Day</B>&#148; means any weekday on which the Principal Trading Market is open for trading. If the Common Stock is not
listed or admitted for trading, &#147;Trading Day&#148; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in New York City are authorized or required
by law or other governmental action to close. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>Transfer Agent</B>&#148; means Computershare Trust Company, N.A., the
Company&#146;s transfer agent and registrar for the Common Stock, and any successor appointed in such capacity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <I>Issuance of
Securities; Registration of Warrants</I>. The Warrant, as initially issued by the Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable under the Registration Statement.
Accordingly, the Warrant and, assuming issuance pursuant to the Registration Statement or an exchange meeting the requirements of Section&nbsp;3(a)(9) of the Exchange Act as in effect on the Original Issue Date, the Warrant Shares, are not
&#147;restricted securities&#148; under Rule 144 promulgated under the Securities Act. The Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &#147;<B>Warrant Register</B>&#148;), in
the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <I>Registration of Transfers</I>. Subject to compliance with all applicable securities
laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such
registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a &#147;<B>New Warrant</B>&#148;) evidencing the portion of this Warrant so transferred shall be issued to the
transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such
transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company&#146;s own expense any
New Warrant under this Section&nbsp;3. Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any notice to the
contrary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <I>Exercise and Duration of Warrants. </I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) All or any part of this Warrant shall be exercisable by the registered Holder in the manner set forth in Section&nbsp;10 at any time and
from time to time on or after the Original Issue Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Holder may exercise this Warrant by delivering to the Company an exercise
notice, in the form attached as Schedule 1 hereto (the &#147;<B>Exercise Notice</B>&#148;), completed and duly signed. The date on which such exercise notice is delivered to the Company (as determined in accordance with the notice provisions hereof)
is an <B>&#147;Exercise Date</B>.&#148; The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the
original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of
this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <I>Delivery of Warrant Shares. </I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Upon exercise of this Warrant, the Company shall promptly (but in no event later than three (3)&nbsp;Trading Days after the Exercise Date),
upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder&#146;s or its designee&#146;s balance account with The Depository Trust Company
(&#147;<B>DTC</B>&#148;) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in the Fast Automated Securities Transfer Program or if the certificates are required to bear a legend regarding
restriction on transferability, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company&#146;s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. The Holder, or any
natural person or legal entity (each, a &#147;<B>Person</B>&#148;) so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date
such Warrant Shares are credited to the Holder&#146;s DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To the extent permitted by law, the Company&#146;s obligations to issue and deliver Warrant Shares in accordance with and subject to the
terms hereof (including the limitations set forth in Section&nbsp;11 below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the
recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or
any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares.
Nothing herein shall limit the Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the
Company&#146;s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <I>Charges, Taxes and Expenses</I>. Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be
made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall be
paid by the Company; <I>provided</I>, <I>however</I>, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or the Warrants in a name
other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <I>Replacement of Warrant</I>. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in
exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case)
and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other
reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company&#146;s
obligation to issue the New Warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <I>Reservation of Warrant Shares</I>. The Company covenants that it will, at all times
while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as
herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into
account the adjustments and restrictions of Section&nbsp;9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly
and validly authorized, issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may be issued as provided
herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. The Company further covenants that it will not, without the
prior written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <I>Certain Adjustments</I>. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant (the &#147;<B>Number of
Warrant Shares</B>&#148;) are subject to adjustment from time to time as set forth in this Section&nbsp;9. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Dividends and
Splits</U>. If the Company, at any time while this Warrant is outstanding, (i)&nbsp;pays a stock dividend on its Common Stock that is payable in shares of Common Stock, (ii)&nbsp;subdivides its outstanding shares of Common Stock into a larger number
of shares of Common Stock, (iii)&nbsp;combines its outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv)&nbsp;issues by reclassification of shares of capital stock any additional shares of Common Stock of the
Company, then in each such case the Number of Warrant Shares shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately after such event and the denominator of which shall be the
number of shares of Common Stock outstanding immediately before such event. Any adjustment made pursuant to clause (i)&nbsp;of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to
receive such dividend or distribution, provided, however, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Number of Warrant Shares shall be recomputed accordingly as of the close of
business on such record date and thereafter the Number of Warrant Shares shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii)&nbsp;or (iii) of this paragraph shall
become effective immediately after the effective date of such subdivision or combination. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Pro Rata Distributions</U>. If the
Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for no consideration (i)&nbsp;evidences of its indebtedness, (ii)&nbsp;any security (other than a distribution of Common Stock covered by the
preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security (including Common Stock), or (iv)&nbsp;cash or any other asset (in each case, a &#147;<B>Distribution</B>&#148;), other than a reclassification as to which
Section&nbsp;9(c) applies, then in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the ownership limitation set forth in Section&nbsp;11(a) hereof)
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for the
participation in such Distribution;<I> provided</I>, <I>however</I>, to the extent that the Holder&#146;s right to participate in any such Distribution would result in the Holder exceeding the ownership limitation set forth in Section&nbsp;11(a)
hereof, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held
in abeyance for the benefit of the Holder until such time, if ever, as the delivery to such Holder of such portion would not result in the Holder exceeding the ownership limitation set forth in Section&nbsp;11(a) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Fundamental Transactions</U>. If, at any time while this Warrant is outstanding (i)&nbsp;the Company effects any merger or consolidation
of the Company with or into another Person, in which the Company is not the surviving entity, (ii)&nbsp;the Company effects any sale to another Person of all or substantially all of its assets in one transaction or a series of related transactions,
(iii)&nbsp;pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital stock of the Company and the Company or such
other Person, as applicable, accepts such tender for payment, (iv)&nbsp;the Company consummates a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, <FONT
STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for any such transaction in which the
stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or (v)&nbsp;the Company effects any reclassification of the Common
Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by
Section&nbsp;9(a) above) (in any such case, a &#147;<B>Fundamental Transaction</B>&#148;), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities,
cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the Number of Warrant Shares (in the case of clause
(iii)&nbsp;above, assuming it had tendered, and the offeror had accepted, such Warrant Shares) (the &#147;<B>Alternate Consideration</B>&#148;). The Company shall not effect any Fundamental Transaction in which the Company is not the surviving
entity or the Alternate Consideration includes securities of another Person unless (i)&nbsp;the Alternate Consideration is solely cash and the Company provides for the simultaneous &#147;cashless exercise&#148; of this Warrant pursuant to
Section&nbsp;10 below or (ii)&nbsp;prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to
the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph (c)&nbsp;shall similarly apply to
subsequent transactions analogous of a Fundamental Transaction type. Notwithstanding the foregoing, in the event of a Fundamental Transaction where the consideration payable to holders of Common Stock consists solely of cash, solely of Marketable
Securities or a combination of cash and Marketable Securities, then this Warrant shall automatically be deemed to be exercised in full in a &#147;cashless exercise&#148; pursuant to Section&nbsp;10 below effective immediately prior to and contingent
upon the consummation of such Fundamental Transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Exercise Price</U>. Simultaneously with any adjustment to the Number of Warrant
Shares pursuant to Section&nbsp;9 the Exercise Price shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased Number of Warrant Shares shall be the
same as the aggregate Exercise Price in effect immediately prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the par value of the Common Stock then in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Calculations</U>. All calculations under this Section&nbsp;9 shall be made to the nearest
<FONT STYLE="white-space:nowrap">one-hundredth</FONT> of one cent or the nearest whole share, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Notice of
Adjustments</U>. Upon the occurrence of each adjustment pursuant to this Section&nbsp;9, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this
Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable),
describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the
Company&#146;s transfer agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Notice of Corporate Events</U>. If, while this Warrant is outstanding, the Company
(i)&nbsp;declares a dividend or any other distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the
Company or any subsidiary, (ii)&nbsp;authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii)&nbsp;authorizes the voluntary dissolution, liquidation or winding up of
the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder a notice of such
transaction at least ten (10)&nbsp;days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to
deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters into any agreement
contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by Section&nbsp;9(c), other than a Fundamental Transaction under clause (iii)&nbsp;of Section&nbsp;9(c), then, except if such notice and the contents thereof
shall be deemed to constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10)&nbsp;days prior to the date such Fundamental
Transaction is consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <I>Cashless Exercise</I>. Notwithstanding anything contained herein to the contrary, this Warrant may
only be exercised through a &#147;cashless exercise.&#148; Upon exercise, the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section&nbsp;3(a)(9) of the Securities Act as determined
as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">X = Y <FONT STYLE="white-space:nowrap">[(A-B)/A]</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">where: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;X&#148; equals
the number of Warrant Shares to be issued to the Holder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;Y&#148; equals the total number of Warrant Shares with respect to which
this Warrant is then being exercised; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;A&#148; equals the Closing Sale Price per share of Common Stock as of the Trading Day on the
date immediately preceding the Exercise Date; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;B&#148; equals the Exercise Price per Warrant Share then in effect on the
Exercise Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the
Warrant Shares issued in such a &#147;cashless exercise&#148; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally
issued (provided that the Commission continues to take the position that such treatment is proper at the time of such exercise). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In no
event will the exercise of this Warrant be settled in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <I>Limitations on Exercise. </I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall
not be entitled to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving effect or immediately prior to such exercise, would cause (i)&nbsp;the aggregate number of shares of Common Stock
beneficially owned by the Holder, its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act to exceed 4.99% (the &#147;<B>Maximum
Percentage</B>&#148;) of the total number of issued and outstanding shares of Common Stock of the Company following such exercise, or (ii)&nbsp;the combined voting power of the securities of the Company beneficially owned by the Holder and its
Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act to exceed 4.99% of the combined voting power of all of the securities of
the Company then outstanding following such exercise. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x)&nbsp;the
Company&#146;s most recent Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as the case may be, filed with the Commission prior to the date hereof, (y)&nbsp;a more recent public announcement by
the Company or (z)&nbsp;any other notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three (3)&nbsp;Trading Days
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
confirm in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the
Holder may from time to time increase or decrease the Maximum Percentage to any other percentage specified not in excess of 19.99% specified in such notice; provided that any such increase will not be effective until the sixty-first (61st) day after
such notice is delivered to the Company. For purposes of this Section&nbsp;11(a), the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial
ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act shall include the shares of Common Stock issuable upon the exercise of this Warrant with respect to which such determination
is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (x)&nbsp;exercise of the remaining unexercised and <FONT STYLE="white-space:nowrap">non-cancelled</FONT> portion of this Warrant by the Holder and
(y)&nbsp;exercise or conversion of the unexercised, <FONT STYLE="white-space:nowrap">non-converted</FONT> or <FONT STYLE="white-space:nowrap">non-cancelled</FONT> portion of any other securities of the Company that do not have voting power
(including without limitation any securities of the Company which would entitle the holder thereof to acquire at any time Common Stock, including without limitation any debt, preferred stock, right, option, warrant or other instrument that is at any
time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock), is subject to a limitation on conversion or exercise analogous to the limitation contained herein and is beneficially owned
by the Holder or any of its Affiliates and other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) This Section&nbsp;11 shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to
determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in Section&nbsp;9(c) of this Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <I>No Fractional Shares</I>. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any
fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any
such fractional shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <I>Notices</I>. Any and all notices or other communications or deliveries hereunder (including, without
limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i)&nbsp;the date of transmission, if such notice or communication is delivered via confirmed
<FONT STYLE="white-space:nowrap">e-mail</FONT> prior to 5:30 P.M., New York City time, on a Trading Day, (ii)&nbsp;the next Trading Day after the date of transmission, if such notice or communication is delivered via confirmed <FONT
STYLE="white-space:nowrap">e-mail</FONT> on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii)&nbsp;the Trading Day following the date of mailing, if sent by nationally recognized overnight courier
service specifying next business day delivery, or (iv)&nbsp;upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery. The addresses and <FONT STYLE="white-space:nowrap">e-mail</FONT> addresses for such
communications shall be: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If to the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Terns Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">1065 East Hillsdale Blvd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Suite 100 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Foster City,
California 94404 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Telephone: [__] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Email: [__]
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If to the Holder, to its address or <FONT STYLE="white-space:nowrap">e-mail</FONT> address set forth herein or on the books and records
of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Or, in each of the above instances, to such other address or <FONT STYLE="white-space:nowrap">e-mail</FONT> address as
the recipient party has specified by written notice given to each other party at least five (5)&nbsp;days prior to the effectiveness of such change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <I>Warrant Agent</I>. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10)&nbsp;days&#146; notice to the
Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or
any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor
warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#146;s last address as shown on the Warrant Register. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <I>Miscellaneous. </I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>No Rights as a Stockholder</U>. The Holder, solely in such Person&#146;s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall
anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&#146;s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any
corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the
issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase
any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Authorized Shares</U>. Except and to the extent as waived or consented to by the
Holder, the Company shall not by any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be
necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount
payable therefor upon such exercise immediately prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> Warrant Shares upon the exercise of this Warrant, and (iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having
jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Successors and
Assigns</U>. Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a
Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to
any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Amendment and Waiver</U>. Except as otherwise provided herein, this Warrant may be modified or amended or the provisions hereof waived
with the written consent of the Company and the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Acceptance</U>. Receipt of this Warrant by the Holder shall constitute
acceptance of and agreement to all of the terms and conditions contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Governing Law; Jurisdiction</U>. ALL QUESTIONS
CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF.
EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION
HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY
CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA
REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING
CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit
or affect any of the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. In case any one or more of the provisions of this Warrant shall be
invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree
upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">REMAINDER OF PAGE INTENTIONALLY LEFT BLANK. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of
the date first indicated above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TERNS PHARMACEUTICALS, INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to Warrant Agreement </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF EXERCISE NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[To be executed by the Holder to purchase shares of Common Stock under the Warrant] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) The undersigned is the Holder of
Warrant No. ___ (the &#147;Warrant&#148;) issued by Terns Pharmaceuticals, Inc., a Delaware corporation (the &#147;Company&#148;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) The undersigned hereby exercises its right to purchase ___________ Warrant Shares pursuant to the Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) The Holder intends that payment of the Exercise Price shall be made as a &#147;Cashless Exercise&#148; under Section&nbsp;10 of the Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the Warrant. The
Warrant Shares shall be delivered to the following DWAC Account Number: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) By its delivery of this Exercise Notice, the undersigned represents and
warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section&nbsp;13(d) of the Securities Exchange Act
of 1934, as amended) permitted to be owned under Section&nbsp;11(a) of the Warrant to which this notice relates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name of Holder: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant) </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>d878008dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERNS PHARMACEUTICALS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT TO PURCHASE COMMON STOCK </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Number of Shares: [_________]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">(subject to adjustment)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Warrant No. [___]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Original Issue Date: September [___], 2024</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Terns Pharmaceuticals, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), hereby certifies that,
for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [___________] or its registered assigns (the &#147;<B>Holder</B>&#148;) is entitled, subject to the terms set forth below, to purchase from the
Company up to a total of [______] shares of common stock, $0.0001 par value per share (the &#147;<B>Common Stock</B>&#148;), of the Company (each such share, a &#147;<B>Warrant Share</B>&#148; and all such shares, the &#147;<B>Warrant
Shares</B>&#148;) at an exercise price per share equal to $0.0001 per share (as adjusted from time to time as provided in Section&nbsp;9 herein, the &#147;<B>Exercise Price</B>&#148;) upon surrender of this Warrant to Purchase Common Stock
(including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the &#147;<B>Warrant</B>&#148;) at any time and from time to time on or after the date hereof (the &#147;<B>Original Issue Date</B>&#148;), subject
to the following terms and conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <I>Definitions</I>. For purposes of this Warrant, the following terms shall have the following
meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Affiliate</B>&#148; means any Person directly or indirectly controlled by, controlling or under common control
with, a Holder, as such terms are used in and construed under Rule 405 under the Securities Act, but only for so long as such control shall continue. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Commission</B>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Closing Sale Price</B>&#148; means, for any security as of any date, the last trade price for such security on the Principal
Trading Market for such security, as reported by Bloomberg L.P., or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate the last trade price, then the last trade price of such security prior to 4:00
P.M., New York City time, as reported by Bloomberg L.P., or if the security is not listed for trading on a national securities exchange or other trading market on the relevant date, the last quoted bid price for the security in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the relevant date as reported by OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices). If
the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder.
If the Company and the Holder are unable to agree upon the fair market value of such security, then the Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of Directors&#146;
determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation
period. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Marketable Securities</B>&#148; means securities meeting all of the following
requirements: (i)&nbsp;the issuer thereof is then subject to the reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), and is then current in its
filing of all required reports and other information under the Securities Act and the Exchange Act; (ii)&nbsp;the class and series of shares or other security of the issuer that would be received by Holder in connection with the Fundamental
Transaction (as defined below) were Holder to exercise this Warrant on or prior to the closing thereof is then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, and (iii)&nbsp;following the closing of such Fundamental Transaction, the Holder would not be restricted from publicly <FONT STYLE="white-space:nowrap">re-selling</FONT> all of the
issuer&#146;s shares and/or other securities that would be received by the Holder in such Fundamental Transaction were the Holder to exercise or convert this Warrant in full on or prior to the closing of such Fundamental Transaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Principal Trading Market</B>&#148; means the national securities exchange or other trading market on which the Common Stock is
primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Select Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)
&#147;<B>Registration Statement</B>&#148; means the Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-</FONT> 269508), that became effective on
February&nbsp;10, 2023. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B>Trading Day</B>&#148; means any weekday on which the Principal Trading Market is open for trading. If the Common Stock is not
listed or admitted for trading, &#147;Trading Day&#148; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in New York City are authorized or required
by law or other governmental action to close. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>Transfer Agent</B>&#148; means Computershare Trust Company, N.A., the
Company&#146;s transfer agent and registrar for the Common Stock, and any successor appointed in such capacity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <I>Issuance of
Securities; Registration of Warrants</I>. The Warrant, as initially issued by the Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable under the Registration Statement.
Accordingly, the Warrant and, assuming issuance pursuant to the Registration Statement or an exchange meeting the requirements of Section&nbsp;3(a)(9) of the Exchange Act as in effect on the Original Issue Date, the Warrant Shares, are not
&#147;restricted securities&#148; under Rule 144 promulgated under the Securities Act. The Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &#147;<B>Warrant Register</B>&#148;), in
the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <I>Registration of Transfers</I>. Subject to compliance with all applicable securities
laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such
registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a &#147;<B>New Warrant</B>&#148;) evidencing the portion of this Warrant so transferred shall be issued to the
transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such
transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company&#146;s own expense any
New Warrant under this Section&nbsp;3. Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any notice to the
contrary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <I>Exercise and Duration of Warrants. </I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) All or any part of this Warrant shall be exercisable by the registered Holder in the manner set forth in Section&nbsp;10 at any time and
from time to time on or after the Original Issue Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Holder may exercise this Warrant by delivering to the Company an exercise
notice, in the form attached as Schedule 1 hereto (the &#147;<B>Exercise Notice</B>&#148;), completed and duly signed. The date on which such exercise notice is delivered to the Company (as determined in accordance with the notice provisions hereof)
is an <B>&#147;Exercise Date</B>.&#148; The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the
original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of
this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <I>Delivery of Warrant Shares. </I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Upon exercise of this Warrant, the Company shall promptly (but in no event later than three (3)&nbsp;Trading Days after the Exercise Date),
upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder&#146;s or its designee&#146;s balance account with The Depository Trust Company
(&#147;<B>DTC</B>&#148;) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in the Fast Automated Securities Transfer Program or if the certificates are required to bear a legend regarding
restriction on transferability, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registered in the Company&#146;s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. The
Holder, or any natural person or legal entity (each, a &#147;<B>Person</B>&#148;) so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective
of the date such Warrant Shares are credited to the Holder&#146;s DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To the extent permitted by law, the Company&#146;s obligations to issue and deliver Warrant Shares in accordance with and subject to the
terms hereof (including the limitations set forth in Section&nbsp;11 below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the
recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or
any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares.
Nothing herein shall limit the Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the
Company&#146;s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <I>Charges, Taxes and Expenses</I>. Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be
made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall be
paid by the Company; <I>provided</I>, <I>however</I>, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or the Warrants in a name
other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <I>Replacement of Warrant</I>. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in
exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case)
and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other
reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company&#146;s
obligation to issue the New Warrant. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <I>Reservation of Warrant Shares</I>. The Company covenants that it will, at all times
while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as
herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into
account the adjustments and restrictions of Section&nbsp;9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly
and validly authorized, issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may be issued as provided
herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. The Company further covenants that it will not, without the
prior written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <I>Certain Adjustments</I>. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant (the &#147;<B>Number of
Warrant Shares</B>&#148;) are subject to adjustment from time to time as set forth in this Section&nbsp;9. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Dividends and
Splits</U>. If the Company, at any time while this Warrant is outstanding, (i)&nbsp;pays a stock dividend on its Common Stock that is payable in shares of Common Stock, (ii)&nbsp;subdivides its outstanding shares of Common Stock into a larger number
of shares of Common Stock, (iii)&nbsp;combines its outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv)&nbsp;issues by reclassification of shares of capital stock any additional shares of Common Stock of the
Company, then in each such case the Number of Warrant Shares shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately after such event and the denominator of which shall be the
number of shares of Common Stock outstanding immediately before such event. Any adjustment made pursuant to clause (i)&nbsp;of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to
receive such dividend or distribution, provided, however, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Number of Warrant Shares shall be recomputed accordingly as of the close of
business on such record date and thereafter the Number of Warrant Shares shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii)&nbsp;or (iii) of this paragraph shall
become effective immediately after the effective date of such subdivision or combination. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Pro Rata Distributions</U>. If the
Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for no consideration (i)&nbsp;evidences of its indebtedness, (ii)&nbsp;any security (other than a distribution of Common Stock covered by the
preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security (including Common Stock), or (iv)&nbsp;cash or any other asset (in each case, a &#147;<B>Distribution</B>&#148;), other than a reclassification as to which
Section&nbsp;9(c) applies, then in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the ownership limitation set forth in Section&nbsp;11(a) hereof)
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for the
participation in such Distribution;<I> provided</I>, <I>however</I>, to the extent that the Holder&#146;s right to participate in any such Distribution would result in the Holder exceeding the ownership limitation set forth in Section&nbsp;11(a)
hereof, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held
in abeyance for the benefit of the Holder until such time, if ever, as the delivery to such Holder of such portion would not result in the Holder exceeding the ownership limitation set forth in Section&nbsp;11(a) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Fundamental Transactions</U>. If, at any time while this Warrant is outstanding (i)&nbsp;the Company effects any merger or consolidation
of the Company with or into another Person, in which the Company is not the surviving entity, (ii)&nbsp;the Company effects any sale to another Person of all or substantially all of its assets in one transaction or a series of related transactions,
(iii)&nbsp;pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital stock of the Company and the Company or such
other Person, as applicable, accepts such tender for payment, (iv)&nbsp;the Company consummates a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, <FONT
STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for any such transaction in which the
stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or (v)&nbsp;the Company effects any reclassification of the Common
Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by
Section&nbsp;9(a) above) (in any such case, a &#147;<B>Fundamental Transaction</B>&#148;), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities,
cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the Number of Warrant Shares (in the case of clause
(iii)&nbsp;above, assuming it had tendered, and the offeror had accepted, such Warrant Shares) (the &#147;<B>Alternate Consideration</B>&#148;). The Company shall not effect any Fundamental Transaction in which the Company is not the surviving
entity or the Alternate Consideration includes securities of another Person unless (i)&nbsp;the Alternate Consideration is solely cash and the Company provides for the simultaneous &#147;cashless exercise&#148; of this Warrant pursuant to
Section&nbsp;10 below or (ii)&nbsp;prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to
the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph (c)&nbsp;shall similarly apply to
subsequent transactions analogous of a Fundamental Transaction type. Notwithstanding the foregoing, in the event of a Fundamental Transaction where the consideration payable to holders of Common Stock consists solely of cash, solely of Marketable
Securities or a combination of cash and Marketable Securities, then this Warrant shall automatically be deemed to be exercised in full in a &#147;cashless exercise&#148; pursuant to Section&nbsp;10 below effective immediately prior to and contingent
upon the consummation of such Fundamental Transaction. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Exercise Price</U>. Simultaneously with any adjustment to the Number of Warrant
Shares pursuant to Section&nbsp;9 the Exercise Price shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased Number of Warrant Shares shall be the
same as the aggregate Exercise Price in effect immediately prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the par value of the Common Stock then in effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Calculations</U>. All calculations under this Section&nbsp;9 shall be made to the nearest
<FONT STYLE="white-space:nowrap">one-hundredth</FONT> of one cent or the nearest whole share, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Notice of
Adjustments</U>. Upon the occurrence of each adjustment pursuant to this Section&nbsp;9, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this
Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable),
describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the
Company&#146;s transfer agent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Notice of Corporate Events</U>. If, while this Warrant is outstanding, the Company (i)&nbsp;declares
a dividend or any other distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any
subsidiary, (ii)&nbsp;authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii)&nbsp;authorizes the voluntary dissolution, liquidation or winding up of the affairs of
the Company, then, except if such notice and the contents thereof shall be deemed to constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder a notice of such transaction at least
ten (10)&nbsp;days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or
any defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters into any agreement contemplating or
solicits stockholder approval for any Fundamental Transaction contemplated by Section&nbsp;9(c), other than a Fundamental Transaction under clause (iii)&nbsp;of Section&nbsp;9(c), then, except if such notice and the contents thereof shall be deemed
to constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10)&nbsp;days prior to the date such Fundamental Transaction is
consummated. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <I>Cashless Exercise</I>. Notwithstanding anything contained herein to the contrary,
this Warrant may only be exercised through a &#147;cashless exercise.&#148; Upon exercise, the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section&nbsp;3(a)(9) of the Securities
Act as determined as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">X = Y <FONT STYLE="white-space:nowrap">[(A-B)/A]</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">where: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;X&#148; equals
the number of Warrant Shares to be issued to the Holder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;Y&#148; equals the total number of Warrant Shares with respect to which
this Warrant is then being exercised; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;A&#148; equals the Closing Sale Price per share of Common Stock as of the Trading Day on the
date immediately preceding the Exercise Date; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;B&#148; equals the Exercise Price per Warrant Share then in effect on the
Exercise Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the
Warrant Shares issued in such a &#147;cashless exercise&#148; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally
issued (provided that the Commission continues to take the position that such treatment is proper at the time of such exercise). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In no
event will the exercise of this Warrant be settled in cash. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <I>Limitations on Exercise. </I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall
not be entitled to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving effect or immediately prior to such exercise, would cause (i)&nbsp;the aggregate number of shares of Common Stock
beneficially owned by the Holder, its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act to exceed 4.99% (the &#147;<B>Maximum
Percentage</B>&#148;) of the total number of issued and outstanding shares of Common Stock of the Company following such exercise, or (ii)&nbsp;the combined voting power of the securities of the Company beneficially owned by the Holder and its
Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act to exceed 4.99% of the combined voting power of all of the securities of
the Company then outstanding following such exercise. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x)&nbsp;the
Company&#146;s most recent Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as the case may be, filed with the Commission prior to the date hereof, (y)&nbsp;a more recent public announcement by
the Company or (z)&nbsp;any other notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three (3)&nbsp;Trading Days
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
confirm in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the
Holder may from time to time increase or decrease the Maximum Percentage to any other percentage specified not in excess of 19.99% specified in such notice; provided that any such increase will not be effective until the sixty-first (61st) day after
such notice is delivered to the Company. For purposes of this Section&nbsp;11(a), the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial
ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act shall include the shares of Common Stock issuable upon the exercise of this Warrant with respect to which such determination
is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (x)&nbsp;exercise of the remaining unexercised and <FONT STYLE="white-space:nowrap">non-cancelled</FONT> portion of this Warrant by the Holder and
(y)&nbsp;exercise or conversion of the unexercised, <FONT STYLE="white-space:nowrap">non-converted</FONT> or <FONT STYLE="white-space:nowrap">non-cancelled</FONT> portion of any other securities of the Company that do not have voting power
(including without limitation any securities of the Company which would entitle the holder thereof to acquire at any time Common Stock, including without limitation any debt, preferred stock, right, option, warrant or other instrument that is at any
time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock), is subject to a limitation on conversion or exercise analogous to the limitation contained herein and is beneficially owned
by the Holder or any of its Affiliates and other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) This Section&nbsp;11 shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to
determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in Section&nbsp;9(c) of this Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <I>No Fractional Shares</I>. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any
fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any
such fractional shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <I>Notices</I>. Any and all notices or other communications or deliveries hereunder (including, without
limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i)&nbsp;the date of transmission, if such notice or communication is delivered via confirmed
<FONT STYLE="white-space:nowrap">e-mail</FONT> prior to 5:30 P.M., New York City time, on a Trading Day, (ii)&nbsp;the next Trading Day after the date of transmission, if such notice or communication is delivered via confirmed <FONT
STYLE="white-space:nowrap">e-mail</FONT> on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii)&nbsp;the Trading Day following the date of mailing, if sent by nationally recognized overnight courier
service specifying next business day delivery, or (iv)&nbsp;upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery. The addresses and <FONT STYLE="white-space:nowrap">e-mail</FONT> addresses for such
communications shall be: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Terns Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1065
East Hillsdale Blvd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Suite 100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Foster City, California 94404 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Telephone: [__] </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: [__] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to the Holder, to its address or <FONT STYLE="white-space:nowrap">e-mail</FONT> address set forth herein or on the books and records of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Or, in each of the above instances, to such other address or <FONT STYLE="white-space:nowrap">e-mail</FONT> address as the
recipient party has specified by written notice given to each other party at least five (5)&nbsp;days prior to the effectiveness of such change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <I>Warrant Agent</I>. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10)&nbsp;days&#146; notice to the
Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or
any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor
warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#146;s last address as shown on the Warrant Register. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <I>Miscellaneous. </I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>No Rights as a Stockholder</U>. The Holder, solely in such Person&#146;s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall
anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&#146;s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any
corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the
issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase
any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Authorized Shares</U>. Except and to the extent as waived or consented to by the
Holder, the Company shall not by any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be
necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount
payable therefor upon such exercise immediately prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> Warrant Shares upon the exercise of this Warrant, and (iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having
jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Successors and
Assigns</U>. Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a
Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to
any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Amendment and Waiver</U>. Except as otherwise provided herein, this Warrant may be modified or amended or the provisions hereof waived
with the written consent of the Company and the Holder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Acceptance</U>. Receipt of this Warrant by the Holder shall constitute
acceptance of and agreement to all of the terms and conditions contained herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Governing Law; Jurisdiction</U>. ALL QUESTIONS
CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF.
EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION
HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY
CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA
REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING
CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or
affect any of the provisions hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. In case any one or more of the provisions of this Warrant shall be invalid
or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree upon a
valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">REMAINDER OF PAGE INTENTIONALLY LEFT BLANK. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of
the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TERNS PHARMACEUTICALS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to Warrant Agreement </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF EXERCISE NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[To be executed by the Holder to purchase shares of Common Stock under the Warrant] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) The undersigned is the Holder of
Warrant No. ___ (the &#147;Warrant&#148;) issued by Terns Pharmaceuticals, Inc., a Delaware corporation (the &#147;Company&#148;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) The undersigned hereby exercises its right to purchase ___________ Warrant Shares pursuant to the Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) The Holder intends that payment of the Exercise Price shall be made as a &#147;Cashless Exercise&#148; under Section&nbsp;10 of the Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the Warrant. The
Warrant Shares shall be delivered to the following DWAC Account Number: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) By its delivery of this Exercise Notice, the undersigned represents and
warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section&nbsp;13(d) of the Securities Exchange Act
of 1934, as amended) permitted to be owned under Section&nbsp;11(a) of the Warrant to which this notice relates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name of Holder: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant) </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>d878008dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g878008dsp80.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;12, 2024 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Terns Pharmaceuticals, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">+1 212 230 8800 (t)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">1065 East Hillsdale Blvd., Suite 100</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">+1 212 230 8888 (f)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Foster City, CA 94404</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">www.wilmerhale.com</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Prospectus Supplement to Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT></U>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is furnished to you in connection with (i)&nbsp;the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT>
(File <FONT STYLE="white-space:nowrap">No.&nbsp;333-269508)</FONT> (the &#147;<B>Registration Statement</B>&#148;) filed by Terns Pharmaceuticals, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), with the Securities and Exchange
Commission (the &#147;<B>Commission</B>&#148;) under the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;), for the registration of, among other things, an indeterminate number of shares of common stock, par value $0.0001
per share (the &#147;<B>Common Stock</B>&#148;) of the Company, and warrants to purchase shares of Common Stock, which may be issued from time to time on a delayed or continuous basis by the Company pursuant to Rule 415 under the Securities Act, as
set forth in the Registration Statement and the prospectus contained therein (the &#147;<B>Base Prospectus</B>&#148;) and (ii)&nbsp;the prospectus supplement, dated September&nbsp;9, 2024 (the &#147;<B>Prospectus Supplement</B>&#148; and, together
with the Base Prospectus, the &#147;<B>Prospectus</B>&#148;), relating to the issuance and sale by the Company of 14,064,048&nbsp;shares of Common Stock, including up to 2,145,000 shares of Common Stock issuable upon exercise of an option to
purchase additional shares granted by the Company (collectively, the &#147;<B>Shares</B>&#148;), and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (the &#147;<B>Warrants</B>&#148;) to purchase up to 2,380,952 shares of Common Stock
(the &#147;<B>Warrant Shares</B>&#148;). The Shares and the Warrants are collectively referred to herein as the &#147;Securities&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Securities are to be issued and sold by the Company pursuant to an underwriting agreement, dated as of September&nbsp;10, 2024 (the
&#147;<B>Underwriting Agreement</B>&#148;), entered into by and among the Company and Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters named in the Underwriting Agreement, which is being filed as Exhibit 1.1
to the Company&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed on the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are acting as
counsel for the Company in connection with the issue and sale by the Company of the Securities. We have examined and relied upon copies of the Registration Statement and the Prospectus, as filed with the Commission. We have also examined and relied
upon the Underwriting Agreement, the form of Warrant, the Amended and Restated Certificate of Incorporation of the Company (as amended or restated from time to time), the Amended and Restated Bylaws of the Company (as amended or restated from time
to time), minutes of meetings of the stockholders and the Board of Directors of the Company, including committees thereof, as provided to us by the Company, and such other documents as we have deemed necessary for purposes of rendering the opinion
hereinafter set forth. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g878008dsp80b.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g878008dsp80.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Terns Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;12, 2024 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our examination of the foregoing documents, we have assumed the genuineness of all
signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as copies, the authenticity of the originals of such latter documents and the legal competence of all
signatories to such documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our opinions set forth below are qualified to the extent that they may be subject to or affected by
(i)&nbsp;applicable bankruptcy, insolvency, reorganization, receivership, moratorium, fraudulent transfer, fraudulent conveyance or similar laws relating to or affecting the rights or remedies of creditors generally, (ii)&nbsp;statutory or
decisional law concerning recourse by creditors to security in the absence of notice or hearing, (iii)&nbsp;duties and standards imposed on creditors and parties to contracts, including, without limitation, requirements of good faith, reasonableness
and fair dealing, and (iv)&nbsp;general equitable principles. We express no opinion as to the availability of any equitable or specific remedy upon any breach of any of the agreements as to which we are opining herein, or any of the agreements,
documents or obligations referred to therein, or to the successful assertion of any equitable defenses, inasmuch as the availability of such remedies or the success of any equitable defense may be subject to the discretion of a court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also express no opinion herein as to any provision of any agreement (a)&nbsp;which may be deemed to or construed to waive any right of the
Company, (b)&nbsp;to the effect that rights and remedies are not exclusive, that every right or remedy is cumulative and may be exercised in addition to or with any other right or remedy and does not preclude recourse to one or more other rights or
remedies, (c)&nbsp;relating to the effect of invalidity or unenforceability of any provision of the Warrants on the validity or enforceability of any other provision thereof, (d)&nbsp;which is in violation of public policy, including, without
limitation, any provision relating to indemnification and contribution with respect to securities law matters, (e)&nbsp;which provides that the terms of the Warrants may not be waived or modified except in writing or (f)&nbsp;relating to choice of
law or consent to jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also express no opinion herein as to the laws of any state or jurisdiction other than the state laws
of the State of New York and the General Corporation Law of the State of Delaware. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing, we are of the
opinion that (a)&nbsp;the Shares have been duly authorized for issuance and, when the Shares have been issued and paid for in accordance with the terms and conditions of the Underwriting Agreement, the Shares will be validly issued, fully paid and <FONT
STYLE="white-space:nowrap">non-assessable,</FONT> (b)&nbsp;the Warrants have been duly authorized by the Company and, when the Warrants are executed by the Company and delivered and paid for in accordance with the terms and conditions of the
Underwriting Agreement, will constitute valid and legally binding obligations of the Company, and (c)&nbsp;the Warrant Shares have been duly authorized and reserved for issuance and, when issued, delivered and paid for upon exercise in accordance
with the provisions of the Warrants, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g878008dsp80.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Terns Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;12, 2024 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that we are opining only as to the matters expressly set forth herein, and no
opinion should be inferred as to any other matters. This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or
subsequent legal or factual developments which might affect any matters or opinions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of
this opinion with the Commission in accordance with the requirements of Item 601(b)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act as an exhibit to the Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> to be filed by the Company on the date hereof in connection with the issuance and sale of the Securities and to the use of our name therein and in the Prospectus Supplement under the caption &#147;Legal
Matters.&#148; In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations of the Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ WILMER CUTLER PICKERING </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HALE AND DORR LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WILMER CUTLER PICKERING HALE AND DORR LLP
</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>d878008dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g878008dsp83.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terns Announces Pricing of Upsized $150.15 Million Public Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;10, 2024 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FOSTER CITY, Calif., Sept. 10, 2024
(GLOBE NEWSWIRE) - Terns Pharmaceuticals, Inc. (&#147;Terns&#148; or the &#147;Company&#148;) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases,
including oncology and obesity, today announced the pricing of its upsized underwritten public offering of 11,919,048 shares of its common stock at a public offering price of $10.50 per share, and, in lieu of common stock to certain investors, <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase 2,380,952 shares of its common stock at a public offering price of $10.4999 per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, in each case before underwriting discounts
and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are expected to be approximately $150.15&nbsp;million, excluding any exercise of the
underwriters&#146; option to purchase additional shares. Terns has granted the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to an additional 2,145,000 shares of common stock at the public offering price, less
underwriting discounts and commissions. The offering is expected to close on September&nbsp;12, 2024, subject to customary closing conditions. All of the securities are being offered by Terns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies and TD Cowen are acting as lead book-running managers for the proposed offering. BMO Capital Markets and UBS Investment Bank are also acting as
bookrunners for the proposed offering. Citizens JMP and Mizuho are acting as <FONT STYLE="white-space:nowrap">co-lead</FONT> managers for the proposed offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Terns intends to use the net proceeds from the proposed offering, to fund research, clinical trials, development and manufacturing of the Company&#146;s key
product candidates, including <FONT STYLE="white-space:nowrap">TERN-701,</FONT> <FONT STYLE="white-space:nowrap">TERN-601</FONT> and other programs, including Terns&#146; <FONT STYLE="white-space:nowrap">TERN-800</FONT> series, and for working
capital and general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-269508)</FONT> relating to the securities offered in the public offering was filed with the Securities and Exchange Commission (the &#147;SEC&#148;) on February&nbsp;1, 2023 and declared effective on
February&nbsp;10, 2023. The offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the
offering have been filed with the SEC and are available on the SEC&#146;s website located at www.sec.gov. A final prospectus supplement relating to the offering will be filed with the SEC. Copies of the preliminary prospectus supplement, final
prospectus supplement, and accompanying prospectus relating to this offering, when available, may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">877-821-7388</FONT></FONT> or by email at prospectus_department@jefferies.com or TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">855-495-9846,</FONT></FONT> or by email at TD.ECM_Prospectus@tdsecurities.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press
release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification of these securities under the securities laws of any such state or other jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Terns
Pharmaceuticals </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates
to address serious diseases, including oncology and obesity. Terns&#146; pipeline contains three clinical stage development programs including an allosteric <FONT STYLE="white-space:nowrap">BCR-ABL</FONT> inhibitor, a small-molecule <FONT
STYLE="white-space:nowrap">GLP-1</FONT> receptor agonist, a <FONT STYLE="white-space:nowrap">THR-</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist
nomination candidate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements about Terns Pharmaceuticals, Inc. (the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; or
&#147;our&#148;) within the meaning of the federal securities laws, including the anticipated closing date of the proposed public offering and the Company&#146;s anticipated use of proceeds of the proposed public offering. All statements other than
statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#147;aim,&#148; &#147;anticipate,&#148; &#147;assume,&#148;
&#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;design,&#148; &#147;due,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;objective,&#148;
&#147;plan,&#148; &#147;positioned,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;target,&#148; &#147;will,&#148; &#147;would&#148; and other similar expressions that are predictions of or indicate
future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and
financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon
forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company&#146;s plans to vary materially, including the risks
associated with the initiation, cost, timing, progress, results and utility of the Company&#146;s current and future research and development activities and preclinical studies and clinical trials. These risks are not exhaustive. For a detailed
discussion of the risk factors that could affect the Company and the offering, please refer to the risk factors identified in the Company&#146;s SEC reports, including but not limited to its Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023, and its prospectus supplement. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts for Terns </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Justin Ng </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">investors@ternspharma.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jenna Urban </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Berry&nbsp;&amp; Company Public Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">media@ternspharma.com
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>tern-20240910.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 9/12/2024 8:21:11 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:tern="http://www.ternspharma.com/20240910"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.ternspharma.com/20240910"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tern-20240910_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tern-20240910_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>tern-20240910_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 9/12/2024 8:21:11 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>tern-20240910_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 9/12/2024 8:21:11 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="tern-20240910.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g878008dsp80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g878008dsp80.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /0%U+6M.^)C:!J6M7#:=J5HTFG2>5""LB_?4G9R0.1[=<T
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:0!HV&FV6E6HM;"UBMH Q;RXE"C).2: /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g878008dsp80b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g878008dsp80b.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MM[ S;E7 D&<L,J/Q'(H SM2UV72M82VN(4%K/ [02@DL\JX_=X]2#D>N#Z4
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M5K(5C(.V9]^5YX(Z=Z )[;PY<1MIDLCV0ELYO-D,%L4\[]TT8S\QYPV?P H
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M!8H J+?Q&ZNX7_=BU56=V.!@@G],4 0'7M+6$2F[4*21RIR, $\8R."#].:
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MVT, E,F6+=,*N>RCL/:@"[0!DZEX?M]3CO5DED1KI%3>F,Q[0PR./1B/I0!
M?#%L9KEQ(5$V\J51=Z.QR6#8SP>1_7B@"WI^BV^G74D\+.2\:IM8C"X&"1[G
M"Y^@H ;/HP>\DO(+EH;AI!(&VA@,)LQCOQ^M $7_  C=F;)+1GD:))$D&2,A
ME0*#GUX!^M &M$K1Q(CR&1E !<@ L?7B@!] &7)H<#6,]LCE&FF:5GVC)R^\
MJ?5>V/2@""+PZMLD#6]V\<\ PC[%(ZOGY>G\9_(4 6FT:V?3K2P9I#;VY4[=
MV"^WIDCWP>.XH @'AZ",.+>:2(;B\8^\$)9'/7J-R9_X$: )K+2!9W2R_:'D
M2(.L*$ ; [!FY[]!CV_.@#2H JWUK)=PA(K@PL#G.T,K#!!# ]1S0!D1^$X(
MI8"+J0I$I 4JN1E64@'^$?.3@>@[<4 ;%M9):R.ZLQ+JBG/^R,"@"O;Z/!;6
M]M%&S#[.S,&  ))##G_OHT 5M.\.16#[_M+R-ZE0,_*5R?4\Y)]: '0Z L*F
M%;N3[,2K>7M'W@%&<_\  >GN: (T\.^5,9XKUTF$GF1D1J%4X8$E1P20YR>.
M@H GM]%$%W'*;J1XHY#,(V4?ZPKM+$@>A)QZGZ"@#5H I:KIR:KI[VCR/$&(
M(=,;E(.>,T 4[KPY!<7$T\<SQ&1$78 "@VD=N^0J@CT44 0KX7C58$%VX2*(
MQ?+&JL1@C&0.GS=.G Z4 7)M$AFE:0RN"V.F/0#_ -EH HZGH-U/<2/93B,7
M 99RSX^4D=!M.>A[CK^0!8GT#S3-B]D19A(C@(.8W;<5]CDG!]#0!>@T^.WF
0CD5FR@E !_VW#'\B* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g878008dsp83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g878008dsp83.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MMRIVD CC'! KQ)QY)./\O;_@'U,)PJ0C4I)QA)7BFK-+S3V+%24% !0 4 %
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MS\#OV2"+O_@HW\0Y?O!=0^*17=\V-AC48ST(P*^EQ3Y<IH?W8V_\FL?'9?\
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M2C"/WV\F?/4:<:F<S]HDXN;M==$_,_77XW_"'P[\3_A7XZ\%_P!D:1:WFO\
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MVQUM=*TZ:Z^UW=E;!7R5FN6+%SEQDA6"\55W:W3L**5.3E'W6U:_E_2*<WP
MT*V^?PSK^M^&7COX=3M1$8]0CM=0CA$#W(AOG<2F6)5!5B5&,J <UDZ5-_9_
M/_,OF?<?J'P076M=T36-9\9:S?/I5U;7BQMINEPSW%W9_,KQ:C&ANK*%L$/
MCB-U)4K@TW"'+RV]WMZ;#52<=G:WDCWA",XVB,JQR@R<+@[22IP"2 <_AUH5
M.$=HVMZBYGWV)\8_SZ5>WR)_0* "@ H * "@ ]J-OD&WR(@@ QV';M@#;C'I
MCM6,FY;L?+%=+#B, #TK:"Y58<=/D/%!(4 % !0 4 % !0 4 (0/R]R.E
M!ZC\30 8'N/Q(Z4   ';IP.Y&?<_2@!HC0 @*H&<E<8&?7'3- "E01CIQC@E
M2 .P(P10 %5/!&0/Z=OIP*  HI[<CTR",<#D=QZT (L:)G (+?>;)+''3+9S
2D4 .QC'7Y>.I[<<^M "T ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140478278950304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 10, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001831363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 10,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Terns Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1448275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1065 East Hillsdale Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Foster City<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">525-5535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TERN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ .C L6660>9(9 0  SP,  !,
M  !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !
M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB
M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G
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M+GAM;%!+ 0(4 Q0    ( #HP+%G"Q("([@   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( #HP+%F97)PC$ 8
M )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ .C L622W$;"'!   V!$  !@              ("!#0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( #HP+%F?H!OPL0(
M .(,   -              "  <H,  !X;"]S='EL97,N>&UL4$L! A0#%
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K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  "H4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d878008d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d878008d8k.htm">d878008d8k.htm</File>
    <File>tern-20240910.xsd</File>
    <File>tern-20240910_lab.xml</File>
    <File>tern-20240910_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d878008d8k.htm": {
   "nsprefix": "tern",
   "nsuri": "http://www.ternspharma.com/20240910",
   "dts": {
    "inline": {
     "local": [
      "d878008d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "tern-20240910.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "tern-20240910_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tern-20240910_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-09-10_to_2024-09-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d878008d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-09-10_to_2024-09-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d878008d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.ternspharma.com//20240910/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001193125-24-217444-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-217444-xbrl.zip
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M,32=P:;*5D6RU 7U-Z'O"/A8$@[R<R!X0.CAS.6Z[^,YDQ0=>26] NL6E?>
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MG&HRAD8I/C*TS0MSP[)+(1M<"(YC+4<<!*<T[F\\80>$8\,:"%CG+1<:\^5
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MA"H@XPT1KX>(3A^/-9Q1L;KYE54U+;,R[ED<UKJA-X3O_7C@'_T_4$L#!!0
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MQ6"&RRMWON3 ZL">D"'I4[&ZN3B#[>4H+O@:*@S<XSW*WS&63K(7/B$A88K
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M%/1A(",7MI/<>A/4E.1Q_#6U7';TN0Z"<,YG,@:IMP$L@5"I?.62GF0I3QQ
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M,#@D,++Q%TZO[0,YAW"<G%.E+!FUO]!<7($)!A%K<8*=+3/9G&*Q<],0,I3
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M5!)?%#4Y,..!J+&[IE R9E!TJ)8$F"J7NG$Y21?CE,=R]%D&?%&Z4(M(%,G
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MCXYW?\1L$BZ &R@>W]O2.I$P.]#,:!,;EBRY%:'<R@6?;SZ]MISR'&I/V7
M;SQAYSNL8%6K/S)L)6.BY#+B3^JIN<9:ZU]Y2@/5R](_V:^5&T58$N[&V6V
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MHW(HNTY%FO<%.MHI47TM 7+.I+[,DHU\F'U#2-M^.3XOQUQ%8=X@S)KRR%0
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M3_N[S$'%H54D"GO<$-:,;1<#5QA0BYEH%:@L6$]B\E-KP'C;X;P2KKM@NOO
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MM.>50RQZ4A&"'5$%XW/*XS2#K T0!P>*(S_G>/@!=N3![YA;Y0 5I?P;/^C
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MB)=NF'^A0U)9W[U9@5B2 ]@*?FA%#[04GJULN@1 -\0HS%@DB"CK9[Q,W\9
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M>5&:?6[SRL4:3VB3FF@*!?I8/VRWQA%9&,_.I\,*:SZ$9T+/KSWHK0!R/B+
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MO6UP),!OP=>OO8^&8!Z_Z@]!ZYD(S@#L\R%8>7#!;VYO'^SUUL'2^/,?EO]
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M+9-?8,/:S_27UY(,<KSOVW?]L99 G.C_[D50MWSOH?WK!>]=GV&#'O8&E0P
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MP(!E<'9P)$995FR:-,Y)C$IR@E8,?<Z7\[A0'T#,C]1:-0=0^$]Z:4B8'4P
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M52(.FZB _9B8!G@GCK27+G=)Z@A&]5;+#,W2S-C$\F0=CPPS%7BP$JY%:<$
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M5^#_/,QEMS^X. =,I6/]J[4!_S!Y#L 7.C]@R(([/YT,7U\K=#^Z8TS01Q;
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MJ6DYJ_&+]O>CX\7C[OL2H-2!IPY,92#* JF3!3+JA*T+9:N^]Y\41BT!PP$
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MUYWPTE@F6<A['[T)#\>BV<!34ZGU2G'N0EG?%'&.ZQ+//#A\Q':>[^U!5ZP
M*WV85158?:"BYDA9F7'97VH$85,5CIG"-;I!AF.XA"-1(!XE8"I#N)2%*=$Y
MTD##?1"/OP#8>!08IKP/;1;QF,UXD KVK\Y6I]/9:38B/&%N7V&V"18>+!L.
MF72?<W+;>!$!B7F8:,K5*(WA4BU*.I1%(103Z4VP?Q9L*)#I.H6#1K&:L@1[
M@B28W[B?,Q_!7N RO(+<3V28*B#0D&ML$*1*20]:5J?<@5**[-W?.5@;) I.
MLZ%%0@Y'8F!O/;"%R$*Z'!4@2-IPM$;F0BQD/6?.R0$%:);]1](V9'GGEN3J
M'%S;S,?Z/JNQ].>.I%>76PG/Q:*T9AN.&0O2MMG(-T--S39;([62HS&"@E",
M3:@F-H0\](2Q3!/YJH6&=L1^N_,,_^\?6C/6Y88,O2#U27@:D?S=]L[^01N)
MNB:;[.)#K)E&^$Y\%+$G81-NP^Y0D8EDHI#E659RWY?T+0\RD6-*78L]9:TW
M/!4$A+8S$2QJGKDS3U:\0L9_$C"C6&R.*"G]#";SG5,-Z#OW=3EQRGLK\\[>
M8:?]_&!WC7< Y*NDLB7UM]@][1$K)$OW3 =FT;9P!C)@).+8EB:7_@"[8JEB
MLUGY6S^CG%:A/C;(4@".R545+$6]#"/(( ,@<Q*"E.3C6%3V)C<>K_?1G=(6
M;39RY[\IBSK+1%5RR/2ED"M#TG5AE+3 7U:1OOV/&"$$9%F_WS7?@"V6[-UX
M<W?VE*Z9,A0+))Z&=$X!U!F$:S$3,?9!;J2(-0M1L_P,$%?KG$$X@;"@*[9V
M8Z%L\+*SA<+BX,&I348^>Z%9-T7FP+\#@>K]!?3D<//W=K9I['K*ZDBA,%FH
M1EM?,S/YIC1[)TQJ<<\F"(J*I])0BR"OY%G45M"W##P?1,YJ\=IB6''"9P)0
M!Y5"E\F 9(D_#09Z()%%C#]1TLK8C_A9Q^;*%<RG6!=D3*U:O-DPJS^4-71M
M1,&&;@Y<[)=GCB:1M('0B=E<71$G<@3VEQ@X!_\K$;XJ"6$;):X%O\>9C"5:
M\?2!!<\78);ZBT7;1+>RX90TL<Z?"D'V%YN- 'D"Q*%-EKG_7/'8ISLN9(PH
MJ+B^?+DB$I.322*$MJ3#T$)-[&$F?0O&:9T6V;JD4^Q6RQU]Y:44#4V/SEU,
M?8J0SY"<0FL>+TSR @DCI:TQ,=D?2P=$KDMI-BSV\Q$-(7(RM;0)OV4@\!73
MUO)T;]VX=;ANWDH-Z,756S2>;KQMQG;4C4=V#%#%%#%=@A3ZJC0G& HX11SQ
M8,X7FMKV[8@6>35@=U?_@UE[K4RN&;\?_?+<_%>;B#K3NKWK^][@*P?P#XW@
M?^#L^MEC].P/](@/48W'.&WXW+'Y8R_+;I%4E(N[N7NCSXTF*Z]U6#_1^#*E
MOZE<7@&YT]B5CPJ2TRX9*T*8'*':.3YQ%,FI[;786(0I2D\(I#(L/PC0R"'1
M>9("FRV\\Q0_T2YZ,EFXFTK I].AP=$,,8G%(<VA4.">1Z&F.D5/XY;L8DG$
MY\BT=7BU0@9%LS5-OTX(C;8JJ4*T*Q.!&&-YX'^$9I\ZK:KARA!!+&RDY(__
M>#9T@]BZXJ"+@@"2&*BYX4E_I@"ED;1N(LNPFADD3CC]$(ML+ !_OD=!M.YG
M'&37LRT:6IJL=>9H=+'QJ?D;\O!#G$:)9PHF>/T,;EI0JZKB,0_E7R;7Z+,G
MP(!C/9$1JC6Q"3@OG;91SGGJIX%1!L1$@UU7OD1*S,3"M+E02$LX@,?,$(9R
M/YPKF]5*@Y_:,@>DL&-F'EB^-.4>Z4P<G#K,8BA %"/%9>0*NG5?H*6U'2O6
M(TT\P!\M '.PG;2AC85(2@1+&!<9C^=#G>5-J)"&QHB)X%32S<+9RGZ:3\:@
M1.B#GF@FIT0$#.$N5J%;(AXG+O5H(!*#!NL28[%3-Y4F+("_DCP&?Z8R%OE&
M&BL%-L5Q)UWC&H8BI+2_FPU:!)>P)P02AR3:Z<G,J>N\QTAD8C(A@DF>C )'
ME<5'ZGS0U:A\MLIUEGQ\QA'%H0PRF #=*R11F$&-B8+:V"TLOZ:[J+83I;+/
MN V=MX?:K6&[I+EM$<SRB)GE3&V3*:N>;2/@!<Y@/PU1QHWK=*7O3DJ"G#W8
M_D3@1FE B$GTV>)KU2X?0M"AF$!Q/27(<,U[W1\&3HJTC<N+K)6[8@>;+DUJ
MY$ZN$:/$37["7.!=WL$L)49IDJ&,;899ZY(3\RBA*W 96!EF.AYM<0 [ HU7
M:C_/N:0Z!AD&$%S8S=#9TO2-8380=,!H4,0"H\,0VVNY:%!*82O##FPV#>%M
M>R^U]/DB<9:XZ-214FE@^G\CR&F<#<Q,QY^-QIP!I@TT.6HZA[I,DN(KH8T:
M<"9M>E% $LD(S2X"S(JR#&U0+;,$IGO.]/I@T?D OI+A#/O?-WD9LQ3E'Y7%
M$[6]6XE798+E&M.RD-4BK)J%H+S1VO K 8=#X;"95$'.8J(4.]5CD<+/Q2H4
M;#;*,%A5N&PZI?8TM*VO 2PXVL"K'*;%\ #9&[G]I8NY#Q6(J:$1Y%A1T=DU
MBCJOMHQ.#O22LR@U**9(#Y.VO@VB;PLW$@X$F*S/.GQ<W1BM"*$W4:;2C& X
MU');PIT;OH?&VI=F&O)SQC:?@P*&?+FA  7,]/YD25G]_%2&AZ[3IYOHL68C
M&^ D;HI!.ORAX@\YM;MT%:Q;&F[TR5NU![-CKQ_O*SHC\+/2Y]=Q/>?M[;S0
M.6C+'&JR+<?+I)@S&VH_%")DX%@+PY%!QOZBV0H\7#Y5H(&CL,Y=>K8TSXVX
M=,]"5<]3L6\$Y.,LF^YN.UFHR[/_H9F56W,N0?F'#D6"A5L9+#$%?;.+%X<
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MHJ#M/_>ZG:TNRX1V=P3$;<!DRF(I"MJQ=AED#X7..;[+]$9@4<-XNQ_/3D?
M.@]N,YF+MLF@]IU4S37/6GN9%NT)"13MOJ;=>VS.M>9I;O69%3J<08%L(]CL
M=X/MK8T_)]&;[>UM*Y/C[+_AR^I \' &TX.QL9@H+58F(9*P>@@KYJ;9(!,3
MC](8X(#IL!',.M4*/@(/"H6(#)MHE5AS>YX#?RNHP\?HRKOO9[7KG4?A*KV2
M7WS/1 H79!E?\#$\=[QPL0:+@@1]#G/R-P6JC&=@Z[M,X-#QPL.8 Y#$85F
M(]Z3*6+$=Z%#N#FI&)2;C26K0MM@?8M@S7)"P:I!$2F2%A%[SJ*=$@'P%0J"
MHLL8J%X'\SYHN,UN&X'DC78'Y2*SD9I66=@(>F^V@FZW6W&ONFO9@+S+N0(6
M(^8K@M]K(^<"RQND63-!&"M29<KJZ+WAH#-@IAA_Q7:[N0!SP.N%/4:WA2IU
M,H',?AR7-@$<A07Q!<'(YF/A@ (L@*KWAPZ[)R,]3?+\55BQA5/*Z) -U!P0
M1CQQY^<P?BPXF%+JNJV+-*5%G 5JP_R3$O7AHQGT%"W5V&$')V?(-IG,8<T3
MKJ]%J?DO!Y?((81(":HM=L#3:T<O-FI%M-D@@D3O 3(#:/$/Q!/[]>3<WG\B
M_RAFJB;"@TX:JC:)Z;WT,0(^NW%<^$D$7AI9\"W@B<1,*O([P.H6BY3"&$$F
M0P )CF@+EGF7Y5K:=%[F5VL+4A\H%Q,HKO"YBZZNI/.W[PV[%HMFXW:^)2#V
M0/2@PJD2:+_K]@*O\L>=>-OM^0,K: 4K *ADC8%E:0*T>]S5J&+]U<;&A,VP
MU@/F2E_CTF8C+!V:/DP%?--6*AIU"11 B$86* /W.8O>?<"BB"<P[%2:',2E
M!48P80V)7SZBL7E8\,OVII?YY4>)7/2( N%4=1P$;FYNMC?>;F]U^Z_\)5K$
MW,8</*^&<Q[=D*SO NXYHG0"#B(VE_G,;KFL@"3T/?R.=)%.K3>6V,U>KDK.
MR^' EYLDOACK D!<@K7%ZDU[323"F!,C!'T B!M"]V:C=L 5QINUW#!'QJ6D
MG/"(3B$A ZL3P5.;GS@YHJ'4@4+3%%D6BV58\; L:%V26F[+9TAD$[(53G.=
M^XB[V[#((3@L8IG(E++,?TZO9J!F8RG;C-]0(@+ZU\TP'+@K"5%ON(QMT:)2
M_]&CPER,43@+%JN04_*$8//YO ,7Z$S5#;$^D93:[V:Z[CFW='Z;*X _&@-7
M&S@ ?$ S@>/ 8M==7Q^O.&DJ*#N?4<KTF@G@'0MB6(VI^@;/%J%7F?;X>!"P
M?6H5R+@[;/BM0+_!+A? 4=(<VM<EU4-!3N&XV]KH(I&BC('J]V]$6H 40<(5
MP D_7:&;ZVZ@*H%+HE84V4RE@HSPB)!^$"?Z[]ZU^QN]]KO-?K^,]65!IXFB
M2" ^45NI[%_1DOE?OGKI.] N'4&I40GOEU\N]U\YQ?38;YS*MK&,\Q^*V7OW
M3&)N;;7?;&^UM_MOW@;WRSDZ[ P')_]:V>J7/%JA'8GY_%E@1'Z8:5OKPC^I
ML:5R&?&2JIQ*3Y/+O(!'H;:V[DK.:P25H1IX8]!)ATAG%F,(ORJ[QL6"8LI4
M(3S M;HD0'E7V/X$'8?AL>\VU@X0UMOOA%]$TZ7KK_ALX.N6+K; $FC>3('_
M6?I!C3/M",Q5$4=$LDAC/I\4A"12Z6:C1(PUR,2A;P7-.BBD2OENL6?[@WJ>
MPMT.S8EQXND>[N\U<?^)IEO[8U7DKIYI-FKCF+LF@4\]/[IO#B3-7S3+L5;^
MX3"'W3_+Z:Q5@YG,!(V *4 (H2D):R%6I;$3HUH8^P*S0H?:U1A-'KI@E#$/
M(LO!X**]?W#LP42F=IJK-,W":L(_ L@^'9^W>ZN:*T1K2A$]52DB('A,4S[Z
M?-'V %?=2S^W/^Z?'!U?[5Q>G1R<';?V7OS4W>Z_7Y;=2RJ4+0E^EHK[='1^
MP1*8#JD2_-B.^T8@&P/]8>W !2PU;,X%['X.([@KFXU44?JV\;HT?1EC-$G.
M'CNE9E47[Z]/NY]_:!_:5X367L]S3B\3AT>_(5#+!P8(8_]!(I,O8K$.'"*Y
MQ0HM9?#*]E@+?MUVTZ@='L_YPK0@TNN,6M'/%^SRZ)\0;+/E[[4/(#L_;=O_
M6NSWH\/1YP\MI-"_+=D=#$_1__S//8$0] UX8>=!<*%3!1"^$%.N;?BAO9GC
MQ_:Q4M29L4M?(IN_9)2_RKS,)]XEFDQ*UN*2-;-BC:^@_$>#]5LS]*"<K[O%
MN5C_O3#!<O[>;+@U56C?"5&Y7#9<U*946OJ)B&SW6LM\52BE;8A.9.+,%O1^
MIA79?#A9'SK4^SE"ASM&!]7["C>C7$XR'KC2#= JVG3Y&!T4VK?J\H3!.@ @
MBTDTRS#>.+[]O&4\ZFU^;+<.;(.:)!%VP@P=+51! ,5D1$7\9'&?S6V=JH%K
M+BW9D@*]KC,5E\FZ/5?ZJ:T;4R1^S1MZC#R&++6^DT0521;?NH(^2"JG:ZNH
MJM:7(B3-:5I;JY\3J"V36S3<Y'1];:IXO+[B1EKK:VB:UA>4G:K*F[K0D*S&
M&[S%CEA%5%^W/5:=.BQ/Y=OZHA'BNK8RNZV9'+ A:B>I/ZVMT,%R936D,FA-
M8ZYIN$RN9U\';/=/OE?R9!?AOTB>LNP&FXU)D1?T+G C_/"Z7,DU#08#__*6
M AS=.,.7NN1W9E6YVC),V^Z]XI%NQ%&&J1WVC[EQHWYS7U  +J",>$&3 /OP
M4VA-M9)S 9O$P9MW$_Q(*0OQ4\J *+?VM8\D%A9OR0G140VDH;3C2C<$)87)
MG)6>;VROS>T@QS*Q.K <O <T_2QB!PPJ$]JS-BZ 9K:<I*9!E"7CZH:40,F&
M?DRO\,O1/6+#MA60E1X&[1N;[W8>4IJ##N=:MDG3I,$BHPG4?7G#U#UD35G6
MA-3:5$[@8^5A BW+M=/[.LM6GQ8"@&=^O$S37\COU>:17";EH*3:4-7QG:+3
MSJIO*&F3Y6G.'"_J><4RU&P UA24G5<G.R@F$;3.=*&B2C.GJ<XT<&4X+!:L
M\88$&M, Y6Z&O%M6XL9/P\MQ8&7^37BS&CA62UN3@_=RO39#]]HO=0P"9%CQ
M?0:%4CQVJ%A!M1L)J#T6<&LJC LWP/3C/IRUJ4KI-:.4KEV1:VF.U?PI<SE,
MB[)WOW5AF:;D:OI:4Q*-^+2@CFRM !@C*DD6FJJ5SV$49/MI2OYQ80_X63.J
MK8=ZCEZW_7??1?AWE84@2*1777:(/F;UOK99SFQ=GT%D[QS:=6@LC/:'0D2+
M;X4L']!0RP1K:K.]?LZO8<,4+2<JBRGW+Y%%%KGQ/=4;\<*V_O=$(_%.6U"*
M&Y5VJ+I_]B' @ J8L"3N"LB_H/4'X2/_QP,/U=5/4O/_2B&3LM/I/8.5)R&T
M_)N(7W)2IAM8V.'D<[<.T.D)H)P_8+^G4:=(4\Z^Z#%JU><VW8'0_O7D!4^R
M]\O(*__4ZL(.T)5UW&<5.B'MULU:!NG_X11AX_XI KSH[/ *B_8O)/\-4$L#
M!!0    ( #HP+%FBW*;;/@,  %4+   1    =&5R;BTR,#(T,#DQ,"YX<V2]
M5DUOVS@0O1?H?YC5J056HF6W12W$*;)- P1(T\)-B]X*6AK;Q%*D2E))_.]W
M2$F.[,1>)UFL+Z8Y\V;>?-)''VY+"==HK-!J$J7)( )4N2Z$6DRBVL;<YD)$
M'XY?OCCZ(X[A].S\$F)8.E?9C+&;FYNDF MEM:P=6;!)KDL&<=SI?[SZ#C\:
MZQE,42*W""6W#@W\50M99,/!<)0.TF$R[,,,<F\/"NXP@S%+AXP4W\#[;)AF
M:0HGG^%3L*+@2I38A^IJ9<1BZ>!5_AH"Z%0KA5+B"LZ$XBH77,*WCO&?<*[R
M!$ZDA*F'6:)IT5QCD;16;VV1V7R))7_Y H#RI6RFR&1=3B*?B#8/MS,C$VT6
MK'"&N56%C)1BTD(C\J@'_7?</0P5PDOL&CCG=A9 G<2G9]1#^-1LN/$7MEIR
M4_)0))^9P3@=]# %BC4DL+*8)PM]S4BP;=_+Q<-Q# >#$:.><)1J[$&D4'_O
M07CQC-JC[^0>Y&84 .EX/&9!ND6I<)L1M-;?LD88M+ES1LQJAV?:E*<XY[4D
M5*U^UUR*N< B:%&OEJC<ALZFAN-F@>Z2EV@KGN-CLTUM]5!HQ#9E/S]?? L=
M%QU[ $!H0E%6VCAH>O%"YV%$]F34_XJ[0L3^*DZ'\2A-R%@$ZD'B.ZH([-E$
MNOH^B<BZ.0XF8G<UL3_$_K#+^\.M_^0,;(^UCW_LXT_?'13_O;7P'S#1ZO*Y
M9'J[[>DU45SDS>IJCH?7Y0[YK-[L%H//P]N]CK<W2>LU^.1*:1<<]9GPJA)J
MKMLKNO1-G'6=/,4YA V6<9,;+7'_GF.5T14:)VC5WPU#8V!I<#Z)_,J)NSWS
M2_)90GNF4[GG8'.\O)@1!.7%';T.ZX3SX LO!B^G-Y/+M6G?#I/(4MYE;SS_
MYW K@X\-ER"6%GPHV^ZHO_:T'AV\]W-%&N /WZ?G>Y^(]1O!'+_52I>KAN>I
MSFO_$G7?)ZKXI(C=ZIR:B\">602"'I,IJ?\Z2'W-LV-:(/V+$Z&#TX'_T)^\
MSD+_R%4!C3GHV3MBVT:V[=<6BR_J.)QS+O-:KO/>@EN-?<#MBAV.O&.V&]?>
M=C7K)IEMCW)[TQ_YYJI9.?3S'U!+ P04    "  Z,"Q9F><DL*D&  "D20
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MNXV+\HYKM:7_NE"^BV9_8T?M^1]02P,$%     @ .C L6=N!"6K;!   !2X
M !4   !T97)N+3(P,C0P.3$P7W!R92YX;6S5FEV/XC84AN]7VO_@IC>MU! 2
M9ML%#;.BS$R%.E\"MJUZLS+) :PZ=F2' ?Y]CP-N"819F-U6\5P,D/@]?L]Y
MC(F=7'Y8I9P\@]),BJX7-IH> 1'+A(E9UUMHG^J8,8_HG(J$<BF@ZZU!>Q^N
MWKZY_,;WR?7MX('X9)[GF>X$P7*Y;"13)K3DBQQ#ZD8LTX#XOFW?'W\DOVVZ
MZY A<* :2$IU#HK\O& \Z43-J!4VPZ@1[<H44!./)#2'#FD'811@PPOROA.%
MG3 DO7MR4T019,Q2V)7*;*W8;)Z3[^+O22&ZED( Y[ FMTQ0$3/*R<@Z_H$,
M1-P@/<[)T,@TVM2@GB%I;*-R)O[JF'\38YZ\?4/P#^LH='&TZYEJ;(NQFBC>
MD&J&;INMP(J\7<WJ0+1L%9*PW6X'Q=ER>\VJ6F,'8?#'_=THGD-*?62 S.*]
MKM!-DO^CWC7W+MB<M.TUZ^@BTIV,B]*?D!8YVL)\\FTSWQSRP\AOA8V53KPK
MT^6FJDIR&,*4F->/PT&I3P-79W.J4EJ,JF( --MA,\CI2@J9K@,C"ZYEO$A!
MY/:U)Y(;D;-\/1!3B6*3C$>*NG;F"J9=ST3V;31CZ=LA!OIT3J!\G>%70[,T
MX^"18">E3.'P$7G1^@X/E 2PRD$DD-@P)H'_+NFK#=OM )9QJ0CV*UR TQ W
M9O(Y2("9'EOFC:E0JZ@.?OC4ESAK]"8Z5S3.RU7@9L1(90]R.@'>]2I$P=<T
MU,.T$Y/Z+:>S4PWMB<J&=LGU5%P*255LP^'; VSET;]M$61483P_GN,\9]53
M)=/*XFQ[DY5&I4I =;TH:N"WWB.98E(A;#SBD85&+S(SKBDWYV *2D%RMTG[
MJ,O"(HXW#47+KXQG,QK[F(&B?(!C?O4KK$_%=$1<7UQ'#%ML+6>PV?EDC&4\
ME5994U](99^6S3OGV#P!>L7I/KG&BZ-S(>V)ZT]KS[#%]J,SV#9SPQ!FS"0J
M\@>:GDRM6EM?:-5^+;.?'&.&"P.I,JF*THZPPM"7"YSBUWV9G(GP,Z'J3O0S
M]BW@]XX!OF4<'A;I!-1Y-'=U=4>WZ]5R:CO&:4Q7@P3+P*9LLSA]#;2C0>I.
M\*CQ+<Y6TS&<O23!(NOM"RZ2(3P/966 NF.L-&T1ALXCC+X48>0BPNA?A*ZM
MS;=9]/'MHQK+I7@5P%VY(_AV+5MX[JS02ZD4EV*/ZDG)9V8V?U]#\""&(Q@/
M?%N6%VZR?)(ZI_Q/EIV_NJB.X C'/=>6HCO[,F8^Z2F@YW K:^I+JNS3LG%G
M\\7<S>)/<RG.7.<=ZNK+Z-"KY>3.ALOOZ"\'T9=INA#;98X^%=81<7V)'3%L
ML;FSC3*2G,4L9V)VCS_&BAEKIS&K4M876)5;2\N=S90G!6;( 5XM%?=!S*UH
M]3B=GCXMOA2AOO1><KVE>.'.'LI>-@.M%Z"^G&5%'&>(5GBW7-W96!E!O# 6
MPV@R9CD_^5+R4%=?;H=>+2=W=D_&BIK'Y4;K=")/_KG;$]67T)Y1B\>=_1$[
MQ&Y6\9R*&9QSN[5:6U]8U7XM,]?V06Y24#,<>[\HN<SG.+]G5)SYR-"1$/4E
M^*)M"]*=K9!M.BN<181FQMSF\8TS*5;H:X^PPK/E]S]LEUP&!W6YPP/F\>7-
M&?///(R+1_X&4$L! A0#%     @ .C L60<KG# -&P  P9X   X
M     ( !     &0X-S@P,#AD.&LN:'1M4$L! A0#%     @ .C L691FK 9K
MT@  MS\$ !               ( !.1L  &0X-S@P,#AD97@Q,2YH=&U02P$"
M% ,4    "  Z,"Q9G8JPU*DV  ""XP  $               @ '2[0  9#@W
M.# P.&1E>#0Q+FAT;5!+ 0(4 Q0    ( #HP+%GFQIOAC@X  %\T   0
M          "  :DD 0!D.#<X,# X9&5X-3$N:'1M4$L! A0#%     @ .C L
M6:W%YM0)#0  *"D  !$              ( !93,! &0X-S@P,#AD97@Y.3$N
M:'1M4$L! A0#%     @ .C L6:+<IML^ P  50L  !$              ( !
MG4 ! '1E<FXM,C R-# Y,3 N>'-D4$L! A0#%     @ .C L69GG)+"I!@
MI$D  !4              ( !"D0! '1E<FXM,C R-# Y,3!?;&%B+GAM;%!+
M 0(4 Q0    ( #HP+%G;@0EJVP0   4N   5              "  >9* 0!T
J97)N+3(P,C0P.3$P7W!R92YX;6Q02P4&      @ " #Z 0  ]$\!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>d878008d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tern-20240910.xsd" xlink:type="simple"/>
    <context id="duration_2024-09-10_to_2024-09-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831363</identifier>
        </entity>
        <period>
            <startDate>2024-09-10</startDate>
            <endDate>2024-09-10</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-368">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-09-10_to_2024-09-10"
      id="Hidden_dei_EntityCentralIndexKey">0001831363</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-379">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-380">2024-09-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-381">Terns Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-382">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-383">001-39926</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-384">98-1448275</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-385">1065 East Hillsdale Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-386">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-387">Foster City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-388">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-389">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-390">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-391">525-5535</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-392">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-393">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-394">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-395">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-396">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-397">TERN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-398">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-399">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2024-09-10_to_2024-09-10" id="ixv-400">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
